

EXHIBIT A



Intercompany and Non-Cash Transfers Analysis

May 28, 2020

Table of Contents

Section	Page
I. Intercompany and Non-Cash Transfers Analysis – Objectives and Procedures	7
II. Executive Summary	11
III. Intercompany and Non-Cash Transfers Analysis – Details on Each Intercompany and Non-Cash Transfer	21
A. Intercompany transfers between Purdue and IACs	22
B. Intercompany transfers between Rhodes and IACs	40
C. Intercompany transfers between Rhodes and Purdue	43
D. Non-cash transfers from Purdue to Pharmaceutical Research Associates L.P.	49

Table of Contents – Exhibits

Section	Page
IV. Exhibits	59
Exhibit 1 Intercompany transfers between Purdue and IACs	60
A. Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support	63
B. Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum	72
C. Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services	84
D. Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties	94
E. Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services	101
F. Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space	110
G. Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services	121
H. Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services	133
I. Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services	143
J. Intercompany transfers between Purdue and Mundipharma UK for consulting and legal services	153
K. Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States	159
L. Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot	171
M. Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services	181

Table of Contents – Exhibits

Section	Page
IV. Exhibits	59
Exhibit 1 Intercompany transfers between Purdue and IACs	60
N. Transfer of the Adhansia assets from Purdue Pharma (Canada) to Purdue in 2018	187
O. Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan	192
P. Intercompany transfers between various IACs (E.R.G. Realty Inc., Mundipharma International Limited (USA), One Stamford Realty L.P., Pharma Associates L.P., and Purdue Pharma Technologies Inc.) and Purdue for accounting, HR, and other similar services	202
Q. Intercompany transfers between foreign IACs and Purdue for finished products	203
R. Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements	212
Exhibit 2 Intercompany transfers between Rhodes and IACs	227
A. Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients	229
B. Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage products	244
C. Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline	247
Exhibit 3 Intercompany transfers between Rhodes and Purdue	252
A. Intercompany transfers between Rhodes Pharma and Purdue for contract manufacturing organization services	254
B. Intercompany transfers between Rhodes and Purdue for allocated shared services functions	265

Table of Contents – Exhibits

Section	Page
IV. Exhibits	59
Exhibit 3 Intercompany transfers between Rhodes and Purdue	252
C. Intercompany transfers between Rhodes Pharma and Purdue for licensing generic and branded Dilaudid	274
D. Intercompany transfers between Rhodes Pharma and Purdue for all rights to morphine sulfate extended release generic	275
E. Intercompany transfers between Rhodes Pharma and Purdue pursuant to Butrans AG profit-sharing agreement	279
F. Intercompany transfers between Purdue and Rhodes Tech for active pharmaceutical ingredient	290
Exhibit 4 Non-cash transfers from Purdue to Pharmaceutical Research Associates L.P.	301
A. Transfer from Purdue of its equity interest in Coventry Technologies L.P. to PRA L.P. in 2008	303
B. Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009, and 2013	309
C. Transfer from Purdue of its equity interest in Millsaw Realty L.P. to PRA L.P. in 2009	331
D. Transfer from Purdue of its stock in Kolltan Pharmaceuticals to PRA L.P. in 2009 and 2014	334
E. Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009	345
F. Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010	357
G. Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010	363
H. Transfer from Purdue of its rights to royalty payments from foreign IACs on non-ADF OxyContin to PRA L.P. in 2017	369
I. Transfer from Purdue of all rights to Dilaudid to PRA L.P. in 2017	371
J. Transfer from Purdue of all rights to MS Contin to PRA L.P. in 2017	380

Table of Contents – Appendix

Section	Page
V. Appendices	381
Appendix 1 Relevant SAP company codes and general ledger accounts	382
Appendix 2 List of sources relied upon	394
Appendix 3 Status of AlixPartners' review	398
VI. Disclaimer and Statement of Limiting Conditions	400



I. Intercompany and Non-Cash Transfers Analysis – Objectives and Procedures

I. Intercompany and Non-Cash Transfers Analysis – Objectives

At the direction of the Special Committee of the Board of Directors of Purdue Pharma Inc. (the “Special Committee”) and Davis Polk & Wardwell LLP (“Counsel”), AlixPartners, LLP (“AlixPartners”) has performed a comprehensive intercompany and non-cash transfers analysis.

- This report (the “Intercompany and Non-Cash Transfers Report”) sets forth the results of AlixPartners' intercompany and non-cash transfers analysis (the “Intercompany and Non-Cash Transfers Analysis”) based on the identification and quantification of significant transfers of value on or after January 1, 2008 made as non-cash transfers and cash payments for goods, services and other consideration among Purdue, its parent, Pharmaceutical Research Associates L.P. (“PRA L.P.”), independent associated companies (“IACs”),¹ and Rhodes, as explained in greater detail on the following page.²
- Cash distributions, compensation, legal expenses, pension benefits, travel and expense reimbursements, and other benefits transferred between Purdue, Rhodes, or subsidiaries, on the one hand, and Purdue and Rhodes parent entities (including PRA L.P.), beneficial shareholders, members of the Sackler family or IACs, on the other hand, are discussed separately in our “Cash Transfers of Value Report.”

¹IACs refers to companies where the Sackler family owns a controlling interest.

²Other capitalized terms, such as “Purdue” and “Rhodes,” are defined on the following page.

I. Intercompany and Non-Cash Transfers Analysis – Objectives

The objectives of the Intercompany and Non-Cash Transfers Analysis were to:

1. Identify, quantify, and document the amount of all significant cash payments¹ for goods, services, and other consideration (including, but not limited to, royalties, licensing of rights, business services, and rent) transferred from January 1, 2008 to September 15, 2019 (regardless of the direction of the payment) between:
 - a. Purdue Pharma L.P. (“PPLP”) together with its subsidiaries (collectively, “Purdue”) and IACs;
 - b. Rhodes Technologies (“Rhodes Tech”), Rhodes Pharmaceuticals L.P. (“Rhodes Pharma”) (collectively, “Rhodes”) and IACs; and
 - c. Purdue and Rhodes.²
2. Identify, quantify, and document the amount of all significant non-cash transfers from Purdue to its parent entity, Pharmaceutical Research Associates L.P. (formerly known as Purdue Holdings L.P.), and/or its previous parent entity, PLP Associates Holdings L.P. (collectively, “PRA L.P.”).^{3,4}

AlixPartners has not been asked by the Special Committee or Counsel to perform an assessment of the reasonableness or fair market value of each intercompany or non-cash transfer.

¹Includes transactions settled with cash payments as well as intercompany accruals (see slide 17 for additional information regarding these intercompany accruals).

²Although Rhodes is currently a subsidiary of Purdue, from January 1, 2008 through May 2019, it was not a subsidiary.

³Prior to 2010, PLP Associates Holdings L.P. was Purdue's direct parent entity.

⁴Prior to 2018, PRA L.P. was known as “Purdue Holdings L.P.”

I. Intercompany and Non-Cash Transfers Analysis – Procedures

In order to achieve the objectives of the Intercompany and Non-Cash Transfers Analysis, we reviewed and relied upon the following sources of information from Purdue, Rhodes, and TXP Services Inc. ("TXP")¹:

1. Entity organizational charts;
2. SAP accounting system information (see **Appendix 1** for a description of the relevant SAP company codes and general ledger accounts);
3. Audited financial statements;
4. Internal financial statements, reports, schedules and/or SAP accounting records for PPLP, Rhodes, and other entities in which the Sackler Family members own a controlling interest or which are operated or owned for their benefit (collectively, "Affiliated Entities," including IACs) whose books and records are maintained in the same SAP accounting system as PPLP and Rhodes;
5. Documentation evidencing, supporting or relating to the intercompany and non-cash transfers made by Purdue, Rhodes and the IACs;
6. The October 19, 2018 presentation prepared by Purdue for the Opioid Multidistrict Litigation ("MDL") in the Northern District of Ohio (the "October 19, 2018 MDL Presentation");
7. Purdue, Rhodes, and TXP employees; and
8. The Statements of Financial Affairs and Schedules of Assets and Liabilities filed with the United States Bankruptcy Court for the Southern District of New York in October of 2019.

See **Appendix 2** for a complete list of information and documents relied upon.

¹TXP is an IAC that provides accounting and other administrative services to Purdue and PPI.

AlixPartners

II. Executive Summary

II. Executive Summary

Our analysis identified 37 categories of transfers involving Purdue, Rhodes, the IACs, and PRA L.P. from January 1, 2008 through September 15, 2019 (27 intercompany and 10 non-cash transfers).

Payments From	Payments To	Categories of Transfers	Amount
Purdue	IACs	14	\$ 667,864,826
Purdue	Rhodes	1	644,442,441
Rhodes	Purdue	5	425,483,519
Rhodes	IACs	1	5,251,087
IACs	Purdue	4	683,503,568
IACs	Rhodes	2	140,778,999

The amounts reflected in the table above and throughout this report represent the gross amounts paid in connection with the intercompany transfers between Purdue and the IACs, Purdue and Rhodes, and Rhodes and the IACs. These amounts do not take into account the value of any goods, services, or other consideration received in exchange for these payments.

The 10 non-cash transfers from Purdue to PRA L.P., not included in the table above, totaled \$410.3 million.

II. Executive Summary – Transfers Between Purdue and IACs

From January 1, 2008 to September 15, 2019, the total amount paid by Purdue to the IACs in connection with the intercompany transfers identified below was \$667.9 million.¹

The total amount paid by the IACs to Purdue in connection with the intercompany transfers identified below for the same period was \$683.5 million.

Exhibit	Payments From	Payments To	Description	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
1A	Purdue	Mundipharma International Limited (USA)	Manufacturing services support	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 2,319,638	\$ 1,697,519	\$ 2,612,601	\$ 1,269,165	\$ 7,898,923
1B	Purdue	One Stamford Realty L.P.	Office space and admin services	12,507,183	8,207,931	8,534,562	8,535,468	8,496,208	8,481,795	8,173,413	8,232,156	8,564,790	8,560,951	9,302,860	7,432,750	105,030,067
1C	Purdue	Purdue Pharma Technologies Inc.	Audit, security & EHS services	12,265,934	13,375,232	14,969,462	15,642,715	14,774,911	11,471,790	8,757,337	8,880,547	n/a	n/a	n/a	n/a	100,137,928
1D	Purdue	Purdue Pharma Technologies Inc.	Finished products from 3rd parties	5,760,344	11,802,711	11,092,517	15,467,233	32,866,635	26,307,510	24,181,836	20,311,089	21,279,185	13,055,169	n/a	n/a	182,124,228
1E	Purdue	The P.F. Laboratories	CMO services	11,023,534	4,644,144	1,345,295	732,908	419,424	239,188	305,459	n/a	n/a	n/a	n/a	n/a	18,709,951
1F	Purdue	The Terramar Foundation, Inc.	Office space	1,587,939	1,838,978	1,734,105	2,035,838	1,966,874	2,737,930	2,351,373	2,198,353	2,310,188	2,250,159	1,184,649	n/a	22,196,386
1G	Purdue	TXP Services Inc.	Financial and tax services	1,038,363	971,339	1,876,315	1,908,805	1,870,552	1,849,805	1,262,983	1,226,247	1,388,196	1,555,265	2,502,912	2,559,793	20,010,575
1H	Purdue	Mundipharma Research Limited	R&D services	15,325,659	8,404,405	5,799,177	3,333,509	3,988,844	3,283,531	6,323,734	6,515,115	10,027,865	10,661,390	5,798,491	1,055,733	80,517,452
1I	Purdue	Mundipharma EDO GmbH	R&D services	n/a	n/a	n/a	n/a	n/a	272,178	5,006,885	2,449,651	2,676,142	5,927,652	10,841,236	4,343,161	31,516,905
1J	Purdue	Mundipharma International Limited (UK)	Consulting and legal services	n/a	n/a	n/a	n/a	167,615	514,175	767,271	599,419	596,235	1,146,881	756,514	n/a	4,548,110
1K	Purdue	Mundipharma A.G.	MS Contin royalties	-	2,060,321	2,260,071	1,221,709	1,176,121	1,068,495	1,057,009	803,858	1,169,133	187,567	n/a	n/a	11,004,285
1L	Purdue	Pharmaceutical Research Associates Inc.	Betadine and Senokot royalties	2,542,015	1,771,497	2,112,558	1,992,739	1,700,138	2,036,722	1,785,568	1,833,050	1,838,701	1,766,378	1,968,093	1,482,404	22,829,863
1M	Purdue	Purdue Pharma (Canada)	Manufacturing and packaging services	n/a	1,794,542	2,466,513	2,307,198	5,409,689	5,243,004	4,518,539	3,727,388	3,271,075	4,037,991	4,293,057	4,023,588	41,092,586
1N	Purdue	Purdue Pharma (Canada)	Adhansia assets	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$4,909,566	15,338,000	20,247,566
Subtotal - Purdue to IACs				\$ 62,050,972	\$ 54,871,100	\$ 52,190,576	\$ 53,178,122	\$ 72,837,010	\$ 63,506,124	\$ 64,491,407	\$ 56,776,872	\$ 55,441,148	\$ 50,846,923	\$ 44,169,979	\$ 37,504,593	\$ 667,864,825
1O	E.R.G. Realty	Purdue	Loan	427,330	415,930	237,927	234,310	356,892	348,400	340,200	332,000	349,002	339,780	1,759,611	n/a	5,141,382
1P	Various IACs	Purdue	Accounting, HR & similar services	-	-	-	-	-	-	-	-	-	-	-	-	-
1Q	Foreign IACs	Purdue	Finished products	1,970,427	1,714,390	1,945,014	2,135,280	2,517,290	2,210,809	17,858,921	7,990,859	6,205,309	4,895,976	4,197,159	3,003,145	56,644,578
1R	Foreign IACs	Purdue	Oxycontin royalty payments	75,621,465	75,948,501	84,636,599	91,213,160	83,818,887	48,359,824	46,362,538	38,851,998	36,189,124	15,154,985	14,817,759	10,742,769	621,717,608
Subtotal - IACs to Purdue				\$ 78,019,222	\$ 78,078,821	\$ 86,819,540	\$ 93,582,750	\$ 86,693,069	\$ 50,919,033	\$ 64,561,658	\$ 47,174,856	\$ 42,743,435	\$ 20,390,741	\$ 20,774,528	\$ 13,745,914	\$ 683,503,568

Additional details regarding these intercompany transfers are provided in Exhibits 1A – 1R of this Report.

¹Amounts included throughout this report represent approximates and may include rounding differences. Certain intercompany transfers (i.e., 1C-1G, 1L, and 1R) were accounted for through intercompany charges (i.e., intercompany accruals). See slide 17 for additional information regarding these intercompany accruals.

II. Executive Summary – Transfers Between Rhodes and IACs

From January 1, 2008 to September 15, 2019, Rhodes received a total of \$140.8 million from the IACs in connection with the intercompany transfers described below.

The total amount paid by Rhodes to the IACs in connection with the intercompany transfers identified below for the same period was \$5.3 million.

Exhibit	Payments From	Payments To	Description	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
2A	Various IACs	Rhodes Tech	API purchases	\$ 8,943,253	\$ 7,012,542	\$ 12,628,858	\$ 14,064,482	\$ 12,611,313	\$ 6,332,936	\$ 11,745,047	\$ 10,763,503	\$ 15,073,149	\$ 20,232,476	\$ 11,678,712	\$ 9,656,767	\$ 140,743,038
2B	Foreign IACs	Rhodes Tech	LAM region finished product	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 35,961	n/a	n/a	n/a	\$ 35,961
Subtotal - IACs to Rhodes Tech				\$ 8,943,253	\$ 7,012,542	\$ 12,628,858	\$ 14,064,482	\$ 12,611,313	\$ 6,332,936	\$ 11,745,047	\$ 10,763,503	\$ 15,109,110	\$ 20,232,476	\$ 11,678,712	\$ 9,656,767	\$140,778,999
2C	Rhodes Pharma	Mundipharma Laboratories GMBH	Theophylline	n/a	n/a	n/a	n/a	212,796	506,934	197,148	407,928	1,535,881	518,260	1,368,630	503,510	5,251,087
Subtotal - Rhodes Pharma to IACs				n/a	n/a	n/a	n/a	\$ 212,796	\$ 506,934	\$ 197,148	\$ 407,928	\$ 1,535,881	\$ 518,260	\$ 1,368,630	\$ 503,510	\$ 5,251,087

Additional details regarding these intercompany transfers are provided in Exhibits 2A – 2C of this Report.

II. Executive Summary – Transfers Between Rhodes and Purdue

From January 1, 2008 to September 15, 2019, the total amount paid by Rhodes to Purdue in connection with the intercompany transfers identified below was \$425.5 million.

The total amount paid by Purdue to Rhodes in connection with the intercompany transfers identified below for the same period was \$644.4 million.

Exhibit	Payments From	Payments To	Description	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
3A	Rhodes Pharma	Purdue	CMO services	n/a	n/a	n/a	\$ 17,715,879	\$ 16,328,283	\$ 20,957,916	\$ 27,913,948	\$ 28,333,693	\$ 39,197,037	\$ 41,242,003	\$ 51,499,136	\$ 47,452,993	\$ 290,640,888
3B	Rhodes	Purdue	IT, benefit, distribution & development services	614,157	2,617,172	2,021,638	3,179,619	3,287,299	3,510,246	3,631,699	5,812,386	7,873,883	9,036,033	8,929,007	6,094,845	56,607,982
3C	Rhodes Pharma	Purdue	Dilaudid generic & branded license	-	-	-	-	-	-	-	-	-	-	-	-	-
3D	Rhodes Pharma	Purdue	Morphine Sulfate Extended Release rights	-	-	-	1,228,841	-	-	-	-	-	-	-	-	1,228,841
3E	Rhodes Pharma	Purdue	Butran AG profit-sharing	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	15,568,950	45,764,450	15,672,407	77,005,807
Subtotal - Rhodes to Purdue				\$ 614,157	\$ 2,617,172	\$ 2,021,638	\$ 22,124,339	\$ 19,615,582	\$ 24,468,162	\$ 31,545,647	\$ 34,146,079	\$ 47,070,920	\$ 65,846,986	\$ 106,192,593	\$ 69,220,245	\$ 425,483,519
3F	Purdue	Rhodes Tech	API purchases	71,259,517	77,620,161	70,564,728	54,140,369	54,369,829	52,971,362	52,215,588	33,726,418	42,913,190	44,207,976	45,410,456	45,042,850	644,442,441
Subtotal - Purdue to Rhodes				\$ 71,259,517	\$ 77,620,161	\$ 70,564,728	\$ 54,140,369	\$ 54,369,829	\$ 52,971,362	\$ 52,215,588	\$ 33,726,418	\$ 42,913,190	\$ 44,207,976	\$ 45,410,456	\$ 45,042,850	\$ 644,442,441

Additional details regarding these intercompany transfers are provided in Exhibits 3A – 3F of this Report.

¹Certain intercompany transfers (i.e., 3A-3B and 3E-3F) were accounted for through intercompany charges (i.e., intercompany accruals). See slide 17 for additional information regarding these intercompany accruals.

II. Executive Summary – Transfers Between Purdue and PRA L.P.

Total non-cash transfers from Purdue to PRA L.P. from January 1, 2008 to September 15, 2019 were \$410.3 million.

Exhibit	Transfer From	Transfer To	Description	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
4A	Purdue	PRA L.P.	Equity of Coventry Technologies L.P.	\$ 52,328,000	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 52,328,000
4B	Purdue	PRA L.P.	Stock of Infinity Pharmaceuticals, Inc.	21,160,000	11,830,000	n/a	n/a	n/a	230,095,681	n/a	n/a	n/a	n/a	n/a	n/a	263,085,681
4C	Purdue	PRA L.P.	Equity of Millsaw Realty L.P.	n/a	7,412,000	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	7,412,000
4D	Purdue	PRA L.P.	Stock of Kolltan Pharmaceuticals	n/a	12,950,000	n/a	n/a	n/a	n/a	2,170,802	n/a	n/a	n/a	n/a	n/a	15,120,802
4E	Purdue	PRA L.P.	Stock of Novelos Therapeutics, Inc.	n/a	23,140,097	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	23,140,097
4F	Purdue	PRA L.P.	Equity of Lucien Holdings S.ar.l.	n/a	n/a	(542,000)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	(542,000)
4G	Purdue	PRA L.P.	Equity of New Suffolk Holdings LLP	n/a	n/a	32,761,081	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	32,761,081
4H	Purdue	PRA L.P.	Rights to non-ADF OxyContin	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	n/a	n/a	-
4I	Purdue	PRA L.P.	Rights to Dilaudid	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	16,966,491	n/a	n/a	16,966,491
4J	Purdue	PRA L.P.	Rights to MS Contin	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-	n/a	n/a	-
Total - Purdue to PRA L.P.				\$ 73,488,000	\$ 55,332,097	\$ 32,219,081	n/a	n/a	\$230,095,681	\$ 2,170,802	n/a	n/a	\$ 16,966,491	n/a	n/a	\$410,272,152

All amounts in the table above represent the value attributed to the transfers in Purdue's accounting records and may not reflect the transfers' fair market value. Purdue did not receive any cash consideration for these transfers.

Details regarding these transfers are provided in Exhibits 4A – 4J of this report.

Notes:

4A: The Cash Distribution Reconciliation table in the Cash Transfers of Value Report excludes \$0.3 million in retained earnings and \$0.8 million of accumulated other comprehensive income which are included in the non-cash transfer of Coventry Technologies L.P.

4D: The amount for 2014 includes \$10,722 in cash payments from Purdue to PRA L.P.

II. Executive Summary – Intercompany Charges

For the transfers listed in the table below, Purdue, Rhodes, and the IACs incurred intercompany charges (i.e., I/C accruals) which were settled periodically on a net basis instead of with individual cash payments.¹ 69% of the activity identified in this report to date was accounted for through intercompany charges.²

Transfers Between Purdue and IACs					
Exhibit	Payments From	Payments To	Description	Activity Type	Total
1C	Purdue	Purdue Pharma Technologies Inc.	Audit, security & EHS services	I/C Charges	\$ 100,137,928
1D	Purdue	Purdue Pharma Technologies Inc.	Finished products from 3rd parties	I/C Charges	182,124,228
1E	Purdue	The P.F. Laboratories	CMO services	I/C Charges	18,709,951
1F	Purdue	The Terramar Foundation, Inc.	Office space	I/C Charges	22,196,386
1G	Purdue	TXP Services Inc.	Financial and tax services	I/C Charges	20,010,575
1L	Purdue	Pharmaceutical Research Associates, Inc.	Betadine and Senokot royalties	I/C Charges	22,829,863
1R	Foreign IACs	Purdue	Oxycontin royalty payments	I/C Charges	621,717,608

Transfers Between Rhodes and Purdue					
Exhibit	Payments From	Payments To	Description	Activity Type	Total
3A	Rhodes Pharma	Purdue	CMO services	I/C Charges	\$ 290,640,888
3B	Rhodes	Purdue	IT, benefit, distribution & development services	I/C Charges	56,607,982
3D	Rhodes Pharma	Purdue	Morphine Sulfate Extended Release rights	I/C Charges	1,228,841
3E	Rhodes Pharma	Purdue	Butran AG profit-sharing	I/C Charges	77,005,807
3F	Purdue	Rhodes Tech	API purchases	I/C Charges	644,442,441

Figures quantified above and throughout this report, in connection with the intercompany accruals, represent the total amount charged in connection with goods and services listed, and do not reflect cash payments effected to settle intercompany charges.

As of the date of this report, AlixPartners is awaiting additional information from TXP to verify and/or update the accuracy of certain information contained herein. See **Appendix 3** for the status of AlixPartners' review.

¹"Intercompany charges" refer to amounts recognized in accounting records as a payable or receivable, as opposed to a cash payment.

²69% represents the percentage of the total amount of activity identified for all transaction categories (i.e., transfer from Purdue to IACs, etc.) that was charged to intercompany accounts.

II. Executive Summary – Contracts

The table below summarizes the transfers for which a contract covering all or part the activity has been identified. Full or partial contracts have been identified for 28 of 37 categories of transfers.

Exhibit	Transfer From	Transfer To	Description	Contract Identified?
1A	Purdue	Mundipharma International Limited (USA)	Manufacturing services support	Yes
1B	Purdue	One Stamford Realty L.P.	Office space and admin services	Yes
1C	Purdue	Purdue Pharma Technologies, Inc.	Audit, security & EHS services	Partial
1D	Purdue	Purdue Pharma Technologies, Inc.	Finished products from 3rd parties	Yes
1E	Purdue	The P.F. Laboratories	CMO services	Yes
1F	Purdue	The Terramar Foundation, Inc.	Office space	Yes
1G	Purdue	TXP Services Inc.	Financial and tax services	Yes
1H	Purdue	Mundipharma Research Limited	R&D services	Yes
1I	Purdue	Mundipharma EDO GmbH	R&D services	Yes
1J	Purdue	Mundipharma International Limited (UK)	Consulting and legal services	Yes
1K	Purdue	Mundipharma A.G.	MS Contin royalties	Yes
1L	Purdue	Pharmaceutical Research Associates, Inc.	Betadine and Senokot royalties	Yes
1M	Purdue	Purdue Pharma (Canada)	Manufacturing and packaging services	Yes
1N	Purdue	Purdue Pharma (Canada)	Adhansia assets	Yes
1O	E.R.G. Realty	Purdue	Loan	Yes
1P	Various IACs	Purdue	Accounting, HR & similar services	No
1Q	Foreign IACs	Purdue	Finished products	No
1R	Foreign IACs	Purdue	Oxycontin royalty payments	Yes
2A	Various IACs	Rhodes Tech	API purchases	No
2B	Foreign IACs	Rhodes Tech	LAM region finished product	No
2C	Rhodes Pharma	Mundipharma Laboratories GMBH	Theophylline	Yes
3A	Rhodes Pharma	Purdue	CMO services	Yes
3B	Rhodes	Purdue	IT, benefit, distribution & development services	No
3C	Rhodes Pharma	Purdue	Dilaudid generic & branded license	No
3D	Rhodes Pharma	Purdue	Morphine Sulfate Extended Release rights	No
3E	Rhodes Pharma	Purdue	Butran AG profit-sharing	Yes
3F	Purdue	Rhodes Tech	API purchases	No
4A	Purdue	PRA L.P.	Equity of Coventry Technologies L.P.	Yes
4B	Purdue	PRA L.P.	Infinity Pharmaceuticals, Inc.	Yes
4C	Purdue	PRA L.P.	Millsaw Realty L.P.	Yes
4D	Purdue	PRA L.P.	Kolltan Pharmaceuticals	Yes
4E	Purdue	PRA L.P.	Novelos Therapeutics, Inc.	Yes
4F	Purdue	PRA L.P.	Lucien Holdings S.ar.l	Partial
4G	Purdue	PRA L.P.	New Suffolk Holdings LLP	Yes
4H	Purdue	PRA L.P.	Non-ADF OxyContin	Yes
4I	Purdue	PRA L.P.	Dilaudid	Yes
4J	Purdue	PRA L.P.	MS Contin	No
				Yes: 26
				Partial: 2
				No: 9
				Total: 37

II. Executive Summary – Reconciliation of Intercompany Transfers with the October 19, 2018 MDL Presentation

The table below compares the amounts of intercompany transfers reflected in the October 19, 2018 MDL Presentation with the results of AlixPartners' analysis.¹

Exhibit	Payments From	Payments To	Description	2016 (\$ millions)			2017 (\$ millions)			Net Difference
				MDL	AlixPartners	Difference	MDL	AlixPartners	Difference	
1A	Purdue	Mundipharma International Limited (US)	Manufacturing services support	\$ 1.7	\$ 2.3	\$ (0.6)	\$ 2.2	\$ 1.7	\$ 0.5	\$ (0.1)
1B	Purdue	One Stamford Realty L.P.	Office space	Not quantified	8.6	n/a	7.2	8.6	(1.4)	\$ (1.4)
1C	Purdue	Purdue Pharma Technologies Inc.	Audit, security & EHS services	Not quantified	n/a	n/a	Not quantified	n/a	n/a	n/a
1D	Purdue	Purdue Pharma Technologies Inc.	Finished products from 3rd parties	21.3	21.3	-	13.1	13.1	-	-
1E	Purdue	The P.F. Laboratories	CMO services	Not quantified	n/a	n/a	Not quantified	n/a	n/a	n/a
1F	Purdue	The Terramar Foundation, Inc.	Office space	Not quantified	2.3	n/a	2.3	2.3	-	n/a
1G	Purdue	TXP Services Inc.	Financial and tax services	1.4	1.4	-	1.6	1.6	-	-
1H	Purdue	Mundipharma Research Limited	R&D services	9.3	10.0	(0.7)	8.3	10.7	(2.4)	(3.1)
1I	Purdue	Mundipharma EDO GmbH	R&D services	4.2	2.7	1.5	7.1	5.9	1.2	2.7
1J	Purdue	Mundipharma International Limited (UK)	Consulting and legal services	0.5	0.6	(0.1)	0.9	1.1	(0.2)	(0.3)
1K	Rhodes	Mundipharma A.G.	MS Contin royalties	Not quantified	1.2	n/a	Not quantified	0.2	n/a	n/a
1L	Purdue	Pharmaceutical Research Associates Inc.	Betadine and Senokot royalties	Not quantified	0.0	n/a	1.8	1.8	-	n/a
1M	Purdue	Purdue Pharma (Canada)	Manufacturing and packaging services	Not quantified	3.3	n/a	Not quantified	4.0	n/a	n/a
1N	Purdue	Purdue Pharma (Canada)	Adhansia assets	Not quantified	n/a	n/a	Not quantified	n/a	n/a	n/a
1O	E.R.G. Realty	Purdue	Loan	Not quantified	0.3	n/a	Not quantified	0.3	n/a	n/a
1P	Various IACs	Purdue	Accounting, HR & similar services	Not quantified	\$ -	n/a	Not quantified	\$ -	n/a	n/a
1Q	Foreign IACs	Purdue	Finished products	6.2	6.2	-	4.9	4.9	-	-
1R	Foreign IACs	Purdue	Oxycontin royalty payments	36.3	36.2	0.1	15.3	15.2	0.1	0.2

Exhibit	Payments From	Payments To	Description	2016 (\$ millions)			2017 (\$ millions)			Net Difference
				MDL	AlixPartners	Difference	MDL	AlixPartners	Difference	
2A	Various IACs	Rhodes Tech	API purchases	Not quantified	\$ 15.1	n/a	Not quantified	\$ 20.2	n/a	n/a
2B	Foreign IACs	Rhodes Tech	LAM region finished product	Not quantified	0.0	n/a	Not quantified	n/a	n/a	n/a
2C	Rhodes Pharma	Mundipharma Laboratories GMBH	Theophylline	Not quantified	1.5	n/a	Not quantified	0.5	n/a	n/a

Exhibit	Payments From	Payments To	Description	2016 (\$ millions)			2017 (\$ millions)			Net Difference
				MDL	AlixPartners	Difference	MDL	AlixPartners	Difference	
3A	Rhodes Pharma	Purdue	CMO services	\$ 43.6	\$ 39.2	\$ 4.4	\$ 41.2	\$ 41.2	\$ -	\$ 4.4
3B	Rhodes	Purdue	IT, benefit, distribution & development services	7.2	7.9	(0.7)	8.5	9.0	(0.5)	(1.2)
3C	Rhodes Pharma	Purdue	Dilaudid generic & branded license	Not quantified	-	n/a	Not quantified	-	n/a	n/a
3D	Rhodes Pharma	Purdue	Morphine Sulfate Extended Release rights	Not quantified	-	n/a	-	-	-	-
3E	Rhodes Pharma	Purdue	Butran AG profit-sharing	Not quantified	n/a	n/a	15.6	15.6	-	-
3F	Purdue	Rhodes Tech	API purchases	42.9	42.9	-	30.4	44.2	(13.8)	(13.8)

Notes:

1A: The amounts in the October 19, 2018 MDL Presentation appear to be transposed for 2016 and 2017.

1I: The amounts in the October 19, 2018 MDL Presentation were compiled based on accounts payable payment dates, whereas our review compiled amounts based on accounts payable posting dates. The total amount from 2008 to 2019 is unaffected regardless of the method used.

1J: The amounts in the October 19, 2018 MDL Presentation excluded amounts paid for reimbursed meeting expenses and were compiled based on invoiced amounts, whereas our review compiled amounts based on payments net of any realized FX gain or loss. If these adjustments are included, the amount reconciles to our review but for rounding errors.

1R: The amounts in the October 19, 2018 MDL Presentation do not appear to take into consideration amounts deducted and retained from royalties by Pharma Associates L.P. under an agreement with PPLP. If these deductions are included, the amount reconciles to our review.

3A: The 2016 amount in the October 19, 2018 MDL Presentation does not appear to include adjustments made in order to reconcile actual cost of services to the contractually agreed upon cost of services. If these adjustments are included, the amount reconciles to our review.

3B: The amounts in the October 19, 2018 MDL Presentation do not take into consideration \$1.0 million in Drug Safety and R&D charges. If these adjustments are included, the amount reconciles to our review but for rounding errors.

3F: Per discussions with and documents from Rhodes, the 2017 amount of \$30.4 million is incorrect. The correct amount is \$44.2 million.

¹“Not quantified” indicates that the October 19, 2018 MDL Presentation did not present an amount for this intercompany transfer; n/a indicates that there is currently no information available to AlixPartners or a difference cannot be calculated. The October 19, 2018 MDL Presentation discloses amounts for only 2016 and 2017.

II. Executive Summary – Reconciliation of Non-Cash Transfers with the October 19, 2018 MDL Presentation

The table below compares the amounts for non-cash transfers contained in the October 19, 2018 MDL Presentation with the results of AlixPartners' review.

Exhibit	Transfer From	Transfer To	Description	Year	MDL (\$ millions)	AlixPartners (\$ millions)	Difference
4A	Purdue	PRA L.P.	Equity of Coventry Technologies L.P.	2008	\$ 52.3	\$ 52.3	\$ -
4B	Purdue	PRA L.P.	Stock of Infinity Pharmaceuticals, Inc	2008	21.2	21.2	-
4B	Purdue	PRA L.P.	Stock of Infinity Pharmaceuticals, Inc	2009	11.8	11.8	-
4B	Purdue	PRA L.P.	Stock of Infinity Pharmaceuticals, Inc	2013	230.1	230.1	-
4C	Purdue	PRA L.P.	Equity of Millsaw Realty L.P.	2009	7.4	7.4	-
4D	Purdue	PRA L.P.	Stock of Kolltan Pharmaceuticals	2009	13.0	13.0	-
4D	Purdue	PRA L.P.	Stock of Kolltan Pharmaceuticals	2014	2.2	2.2	-
4E	Purdue	PRA L.P.	Stock of Novelos Therapeutics, Inc.	2009	23.1	23.1	-
4F	Purdue	PRA L.P.	Equity of Lucien Holdings S.ar.l.	2010	(0.5)	(0.5)	-
4G	Purdue	PRA L.P.	Equity of New Suffolk Holdings LLP	2010	32.8	32.8	-
4H	Purdue	PRA L.P.	Right to non-ADF OxyContin	2017	-	-	-
4I	Purdue	PRA L.P.	Rights to Dilaudid	2017	16.9	16.9	-
4J	Purdue	PRA L.P.	Rights to MS Contin	2017	-	-	-



III. Intercompany and Non-Cash Transfers Detail

1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

On January 1, 2014, as part of the set up of a global supply chain organization designed to allow planning of supply chain and manufacturing sites on a global basis, Purdue entered into a manufacturing services support agreement with Mundipharma International Limited (USA) ("MIL USA"). On August 3, 2018, Purdue also entered into a service agreement with Mundipharma International Technical Operations Limited ("MITOL"). As part of these agreements, four MIL USA employees were hired to coordinate, manage, expand, or rationalize the global supply chain. Pursuant to the agreement, Purdue agreed to pay MIL USA's costs (the salaries of the four individuals and related costs) plus a 10% markup for manufacturing support services. Per discussions with Purdue, MIL USA did not begin providing these services until 2015, and the first payment for these services occurred in 2016. From January 2018 to September 2019, Purdue paid 50% of MIL USA's costs as well as 50% of MITOL's costs, plus a 10% markup for manufacturing support services, except for salary-related expenses to which a 7.5% markup was applied.

From January 1, 2016 to September 15, 2019, Purdue paid MIL USA \$5.5 million and MITOL \$2.4 million for manufacturing support services.

Year	MIL USA	MITOL	Total
2016	\$ 2,319,638	\$ -	\$ 2,319,638
2017	1,697,519	-	1,697,519
2018	1,433,480	1,179,121	2,612,601
2019	37,168	1,231,997	1,269,165
Total	\$ 5,487,805	\$ 2,411,118	\$ 7,898,923

1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

On April 6, 2006, Purdue entered into a lease agreement with One Stamford Realty L.P. for office space at One Stamford Forum, Stamford, CT. One Stamford Forum is Purdue's headquarters. As of July 1, 2018, Purdue entered into a services agreement with One Stamford Realty L.P. for One Stamford Realty L.P. to provide additional facilities and administrative services related to One Stamford Forum.

From January 1, 2008 to September 15, 2019, Purdue paid One Stamford Realty L.P. \$105.0 million related to its lease of One Stanford Forum.¹

Year	Rent	Electric	Real Estate Tax	Operating Expenses	Administrative Services Fees	Total Payments
2008	\$ 11,232,286	\$ 629,749	\$ 467,192	\$ 177,957	n/a	\$ 12,507,183
2009	6,929,840	683,394	413,073	181,625	n/a	8,207,931
2010	6,872,101	841,979	513,691	306,791	n/a	8,534,562
2011	6,986,608	734,650	530,019	284,191	n/a	8,535,468
2012	6,986,608	710,058	549,499	250,043	n/a	8,496,208
2013	6,986,608	724,127	495,018	276,042	n/a	8,481,795
2014	6,986,608	580,193	442,825	163,787	n/a	8,173,413
2015	7,006,418	507,245	466,461	252,032	n/a	8,232,156
2016	7,224,325	500,637	489,139	350,689	n/a	8,564,790
2017	7,224,325	522,069	513,254	301,303	n/a	8,560,951
2018	7,224,325	579,368	556,504	394,044	548,619	9,302,860
2019	5,418,244	477,244	499,575	378,730	658,957	7,432,750
Total	\$ 87,078,294	\$ 7,490,713	\$ 5,936,250	\$ 3,317,234	\$ 1,207,576	\$ 105,030,067

For additional detail on this transfer, see Exhibit 1B.

¹See **Appendix 3** for the status of our review of electric, real estate taxes, operating expenses and administrative fees.

1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental health & safety services

On January 1, 2008, Purdue entered into a security services agreement with Purdue Pharma Technologies Inc. ("PPTI"). Under this agreement, PPTI provided security services at Purdue's manufacturing facilities and corporate offices, and monitored the security of Purdue's supply chain. In 2008, PPTI also began providing Purdue internal audit and environmental, health, and safety ("EHS") services. These services included, for example, assisting Purdue in complying with DEA regulatory requirements concerning the handling and transportation of potent chemicals. PPTI provided these security, internal audit, and EHS services to Purdue from 2008 to 2015 and charged Purdue its costs plus a 10% markup.

From 2008 to 2015, PPTI charged Purdue \$100.1 million for internal audit, security, and EHS services, including a 10% markup of \$9.1 million.

Year	Security Charges	EHS Charges	Internal Audit Charges	Total Service Charges
2008	\$ 7,483,326	\$ 4,558,375	\$ 224,233	\$ 12,265,934
2009	7,466,631	5,416,074	492,527	13,375,232
2010	8,102,142	6,033,538	833,782	14,969,462
2011	8,165,239	6,746,851	730,625	15,642,715
2012	7,885,712	6,134,915	754,284	14,774,911
2013	6,933,088	3,569,348	969,354	11,471,790
2014	5,192,813	3,079,809	484,715	8,757,337
2015	5,387,673	2,941,390	551,484	8,880,547
Total	\$ 56,616,624	\$ 38,480,300	\$ 5,041,004	\$ 100,137,928

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 1C.

¹Based on our discussions with Purdue and TXP, we understand that there is no written agreement for these services.

1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

On January 1, 2008, Purdue entered into a purchasing services agreement with PPTI, the service provider, under which PPTI agreed to purchase finished products from third parties on behalf of Purdue. All third-party-procured finished products from 2008 to 2017 were initially purchased by PPTI (e.g. Butrans, Betadine, Colace, Senokot) and recharged to Purdue at a [REDACTED] markup.

From 2008 to 2017, PPTI charged Purdue \$182.1 million for finished products, which included [REDACTED] in markups.

Year	Charges for Purchasing Services
2008	\$ 5,760,344
2009	11,802,711
2010	11,092,517
2011	15,467,233
2012	32,866,635
2013	26,307,510
2014	24,181,836
2015	20,311,089
2016	21,279,185
2017	13,055,169
Total	\$ 182,124,228

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 1D.

1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

On January 1, 1996, Purdue entered into a contract manufacturing agreement with The P.F. Laboratories Inc. ("P.F. Labs"). Under this agreement, P.F. Labs agreed to manufacture various dosages of MS Contin for Purdue. In exchange, Purdue agreed to pay P.F. Labs' costs plus a 10% markup. Per discussions with Purdue, this agreement ended in 2014. This manufacturing facility was sold at the end of 2015.

From 2008 to 2014, P.F. Labs charged Purdue \$17 million in manufacturing costs and \$1.7 million in markups, totaling \$18.7 million.

Year	Manufacturing Costs	Service Commissions	Total Charges
2008	\$ 10,021,395	\$ 1,002,139	\$ 11,023,534
2009	4,221,947	422,197	4,644,144
2010	1,222,995	122,300	1,345,295
2011	666,280	66,628	732,908
2012	381,294	38,129	419,424
2013	217,444	21,744	239,188
2014	277,690	27,769	305,459
Total	\$ 17,009,044	\$ 1,700,907	\$ 18,709,951

Payments for these contract manufacturing organization ("CMO") services were settled through intercompany accruals (e.g. cross charges) and subsequent funding.

For additional detail on this transfer, see Exhibit 1E.

1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

On April 13, 1998, Purdue entered into a service agreement with The Terramar Foundation, Inc. ("Terramar") for office space and other services at [REDACTED], New York, NY. Services paid by Purdue included rent, salaries of employees, maintenance, security, and other administrative expenses, plus a 10% markup. This agreement was terminated as of July 1, 2018.

From 2008 to 2018, PPLP was charged approximately \$22.2 million by Terramar, which included \$2.0 million in markups.

Year	Charges for Costs & Expenses	Service Charge	Total
2008	\$ 1,443,581	\$ 144,358	\$ 1,587,939
2009	1,671,798	167,180	1,838,978
2010	1,576,459	157,646	1,734,105
2011	1,850,762	185,076	2,035,838
2012	1,788,067	178,807	1,966,874
2013	2,489,028	248,903	2,737,930
2014	2,137,612	213,761	2,351,373
2015	1,998,502	199,850	2,198,353
2016	2,100,172	210,017	2,310,189
2017	2,045,599	204,560	2,250,159
2018	1,077,073	107,575	1,184,648
Total	\$ 20,178,653	\$ 2,017,733	\$ 22,196,386

Payments for these services were settled through intercompany accruals and subsequent funding. For additional detail on this transfer, see Exhibit 1F.

1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

On January 1, 2008, Purdue entered into a tax services agreement with TXP. Pursuant to this agreement, TXP provided financial and tax-related services to Purdue and charged Purdue its costs and expenses plus a 10% markup. Purdue and TXP entered into a revised agreement as of July 1, 2018 on a fixed-fee basis.

From January 1, 2008 to September 15, 2019, TXP charged Purdue \$20.0 million for financial and tax services, which included \$1.4 million in markups.¹

Year	Cost & Expenses	Markups	Total Charges for Financial & Tax Services
2008	\$ 943,966	\$ 94,397	\$ 1,038,363
2009	883,035	88,304	971,339
2010	1,705,741	170,574	1,876,315
2011	1,735,277	173,528	1,908,805
2012	1,700,502	170,050	1,870,552
2013	1,681,641	168,164	1,849,805
2014	1,148,142	114,841	1,262,983
2015	1,114,770	111,477	1,226,247
2016	1,270,694	117,502	1,388,196
2017	1,413,877	141,388	1,555,265
2018	2,418,975	83,937	2,502,912
2019	2,559,793	-	2,559,793
Total	\$ 18,576,413	\$ 1,434,162	\$ 20,010,575

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 1G.

¹Under the July 1, 2018 agreement and its fixed-fee basis, no further markups were calculated.

1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

In 2003, Purdue entered into a research services agreement with Mundipharma Research Limited (“MRL”) for MRL to provide R&D services to Purdue. These services included consulting on regulatory affairs, technical development, medical research, and project management for OxyContin in foreign countries. The agreement was replaced by a similar agreement dated September 17, 2010. The 2010 agreement was further amended in March 2017 and February 2018 to add and/or replace the covered projects listed in Schedule 2 of the 2010 agreement.¹ In exchange, Purdue agreed to pay MRL’s costs plus a [REDACTED] markup.

From January 1, 2008 to September 15, 2019, Purdue paid MRL \$80.5 million for the R&D services, which included [REDACTED] in markups.²

Year	Invoice Amount
2008	\$ 15,325,659
2009	8,404,405
2010	5,799,177
2011	3,333,509
2012	3,988,844
2013	3,283,531
2014	6,323,734
2015	6,515,115
2016	10,027,865
2017	10,661,390
2018	5,798,491
2019	1,055,733
Total	\$ 80,517,452

For additional detail on this transfer, see Exhibit 1H.

¹Covered projects initially included: OXY Intermediate Strengths (15, 30, 60, 120) and OXY Tamper Resistance (5-80 and 120). Additional covered projects included: SIGMA-1, MUM01, Fibromyalgia syndrome, and ICS/LABA/LAMA triple combination.

²Per discussions with Purdue, the 10% markups are included in the total invoiced amount, and not shown as a separate line item. As such, the service charges are not separately discernable in SAP and this figure is an extrapolation.

1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

On January 18, 2013, PPLP entered into a services agreement with Mundipharma EDO GmbH ("Mundipharma EDO") for R&D services. On the same day, Purdue Pharmaceutical Products L.P. ("PPPLP" or "3XP") entered into a similar services agreement with Mundipharma EDO for R&D services. Pursuant to the terms of these agreements, Mundipharma EDO provided, among other things, consulting services and other project development services in connection with four oncology development programs. Under these agreements, Mundipharma EDO retained experts in oncology who assisted in progressing development programs (e.g., performing early stage clinical trials, formulation, development and non-clinical studies). In exchange, Purdue agreed to pay Mundipharma EDO's costs plus a [REDACTED] markup.

From January 1, 2013 to September 15, 2019, Purdue paid Mundipharma EDO \$31.5 million for the R&D services, which included [REDACTED] in markups.¹

Year	Invoice Amount
2013	\$ 272,178
2014	5,006,885
2015	2,449,651
2016	2,676,142
2017	5,927,652
2018	10,841,236
2019	4,343,161
Total	\$ 31,516,905

For additional detail on this transfer, see Exhibit 1I.

¹Per discussions with Purdue, the [REDACTED] markups are included in the total invoiced amount, and not shown as a separate line item. As such, the service charges are not separately discernable in SAP and this figure is an extrapolation.

1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

On July 4, 2012, Purdue entered into a services agreement with Mundipharma International Limited (UK) ("MIL UK"). Based on discussions with Purdue, the services provided included consulting services (i.e., management consulting and general and administrative services). On January 1, 2015, Purdue entered into a second services agreement with MIL UK, which expanded the scope of services provided to Purdue to include legal services. Pursuant to these agreements, Purdue agreed to pay MIL UK's costs plus a 10% markup. From 2012 to 2018, Purdue paid MIL UK \$4.5 million for these services.¹

Year	Payments
2012	\$ 167,615
2013	514,175
2014	767,271
2015	599,419
2016	596,235
2017	1,146,881
2018	756,514
Total	\$ 4,548,110

For additional detail on this transfer, see Exhibit 1J.

¹See Appendix 3 for the status of our review of charges prior to the 2012 services agreement.

1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

On January 1, 2008, Purdue entered into a license agreement with Mundipharma A.G. under which Purdue obtained the right to manufacture and sell MS Contin in the United States from Mundipharma A.G. Pursuant to the agreement, Purdue agreed to pay Mundipharma A.G. [REDACTED] of its net sales of MS Contin in the United States. Purdue was also obligated to pay Mundipharma A.G. [REDACTED] of its profits from sales of generic versions of MS Contin under a prior license agreement.

From 2009 to 2017, Purdue paid Mundipharma A.G. \$11.0 million in royalties and profit share related to manufacturing and selling branded and authorized generic MS Contin in the United States.^{1,2,3}

Year	Royalty Payments
2009	\$ 2,060,321
2010	2,260,071
2011	1,221,709
2012	1,176,121
2013	1,068,495
2014	1,057,009
2015	803,858
2016	1,169,133
2017	187,567
Total	\$ 11,004,285

For additional detail on this transfer, see Exhibit 1K.

¹Effective May 1, 2017, the manufacturer's license agreement was assigned to Rhodes Pharma. Since May 1, 2017, Rhodes Pharma has accrued \$1.3 million in royalties, but has not made any payments.

²In 2008, royalty and profit share payments of \$2.1 million were paid to Mundipharma A.G. by PLP Associates Holdings L.P., a limited partner of PRA L.P., the parent company of PPLP.

³See Appendix 3 for the status of our review of charges related to meeting and consulting expenses.

1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

On November 29, 2006, Pharmaceutical Research Associates, Inc. and Purdue Products L.P. (n/k/a Avrio Health L.P.) entered into an assignment and assumption agreement under which Avrio Health L.P. received the right to sell Betadine and Senokot in the United States. In exchange, Avrio Health L.P. agreed to pay Pharmaceutical Research Associates Inc. a royalty of ■■■ of its net sales of Betadine and Senokot.

From January 1, 2008 to September 15, 2019, Pharmaceutical Research Associates, Inc. charged Purdue \$22.8 million for royalties due.

Charges for	
Year	Royalties
2008	\$ 2,542,015
2009	1,771,497
2010	2,112,558
2011	1,992,739
2012	1,700,138
2013	2,036,722
2014	1,785,568
2015	1,833,050
2016	1,838,701
2017	1,766,378
2018	1,968,093
2019	1,482,404
Total	\$ 22,829,863

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 1L.

1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services

Effective September 1, 2009, Purdue entered into a supply agreement with Purdue Pharma (Canada) for manufacturing and packaging services.

From September 1, 2009 to September 15, 2019, Purdue paid \$41.1 million to Purdue Pharma (Canada) pursuant to the supply agreement.

Year	Payments
2009	\$ 1,794,542
2010	2,466,513
2011	2,307,198
2012	5,409,689
2013	5,243,004
2014	4,518,539
2015	3,727,388
2016	3,271,075
2017	4,037,991
2018	4,293,057
2019	4,023,588
Total	\$ 41,092,586

For additional detail on this transfer, see Exhibit 1M.

1N: Transfer of the Adhansia assets from Purdue Pharma (Canada) to Purdue in 2018

On October 11, 2018, Purdue entered into an asset purchase agreement with Purdue Pharma (Canada) for the Adhansia assets.

As of September 15, 2019, Purdue has paid Purdue Pharma (Canada) \$20.2 million for the Adhansia assets.

Asset Purchase Agreement Section	Description	Paying Entity	Date	Payment Amount
§2.6.i	Purchase price paid at closing	Purdue Pharma L.P. (208)	12/12/2018	\$4,909,566
2.6.iii and 2.6.iv	FDA expense reimbursement and FDA approval	Adlon Therapeutics L.P. (258) ¹	3/20/2019	8,951,941
§2.6.ii	Costs in respect of the AWE Clinical Trials	Adlon Therapeutics L.P. (258)	4/5/2019	2,386,059
2.6.v	First commercial sale	Adlon Therapeutics L.P. (258)	8/5/2019	4,000,000
Total				\$20,247,566

For additional detail on this transfer, see Exhibit 1N.

¹Adlon Therapeutics L.P. is a subsidiary of PPLP.

10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

In 2000, Purdue loaned \$4.75 million to E.R.G. Realty Inc. The loan had an original repayment date of September 2010. As of January 1, 2008, the loan balance was \$3.85 million. In October 2010, Purdue extended the term of the loan, which had a \$3.45 million balance at the time, to September 2020. The purpose of these loans was to fund renovations to E.R.G. Realty Inc.'s land and buildings in New York City. E.R.G. Realty Inc. paid off the loan in 2018. From 2008 to 2018, E.R.G. Realty Inc. paid Purdue \$5.1 million in principal and interest.

Year	Principal	Interest	Total
2008	\$ 200,000	\$ 227,330	\$ 427,330
2009	200,000	215,930	415,930
2010	100,000	137,927	237,927
2011	100,000	134,310	234,310
2012	250,000	106,892	356,892
2013	250,000	98,400	348,400
2014	250,000	90,200	340,200
2015	250,000	82,000	332,000
2016	275,000	74,002	349,002
2017	275,000	64,780	339,780
2018	1,700,009	59,602	1,759,611
Total	\$ 3,850,009	\$ 1,291,373	\$ 5,141,382

For additional detail on this transfer, see Exhibit 10.

1P: Intercompany transfers between various IACs and Purdue for accounting, HR, and other services

Based on discussions with Purdue and TXP, Purdue provided various IACs¹ accounting, IT, HR, and other services. Per these discussions, no amounts were charged to any of these entities for the services provided by Purdue.

For additional detail, see Exhibit 1P.

¹The IACs include: 1) E.R.G. Realty, Inc, 2) Mundipharma International Limited (USA), 3) One Stamford Realty L.P., 4) Pharmaceutical Research Associates, Inc., 5) Pharma Associates L.P., and 6) Purdue Pharma Technologies Inc.

1Q: Intercompany transfers between foreign IACs and Purdue for finished products

From January 1, 2008 to September 15, 2019, certain foreign IACs paid Purdue \$56.6 million for finished dosage OxyContin and MS Contin for sale in foreign markets (including [REDACTED] relating to freight and [REDACTED] relating to product markups).

Per discussions with Purdue, these finished products sales from Purdue to the various IACs were not governed by a written agreement but were generally priced at cost plus a [REDACTED] or [REDACTED] markup ([REDACTED] between 2011-2015, [REDACTED] between 2016-2019).¹

Year	Total Payments
2008	\$ 1,970,427
2009	1,714,390
2010	1,945,014
2011	2,135,280
2012	2,517,290
2013	2,210,809
2014	17,858,921
2015	7,990,859
2016	6,205,309
2017	4,895,976
2018	4,197,159
2019	3,003,145
Total	\$ 56,644,578

For additional detail on this transfer, see Exhibit 1Q.

¹Per discussions with Purdue, markups between 2008-2010 for foreign markets were extrapolated based on costs and markups in the US Market for the same respective products. In 2011, pricing was consolidated and streamlined to ensure that costs were sufficiently covered by product sales.

1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Purdue licenses the right to manufacture and sell ADF and non-ADF OxyContin to numerous foreign IACs. In exchange, Purdue receives a royalty from the foreign IACs as a percentage of the foreign IACs' sales of OxyContin. On December 15, 2005, Purdue entered into an agreement with Pharma Associates L.P. ("PALP"), an IAC, pursuant to which PALP agreed to collect and pay royalties owed to Purdue from the foreign IACs under the various foreign OxyContin license agreements. In exchange for these services, Purdue agreed to reimburse PALP for its expenses incurred under the agreement plus \$50,000 per year.

From January 1, 2008 to September 15, 2019, PALP and various foreign IACs paid Purdue \$621.7 million in royalties (net of expenses).

Year	Royalty Payments
2008	\$ 75,621,465
2009	75,948,501
2010	84,636,599
2011	91,213,160
2012	83,818,887
2013	48,359,824
2014	46,362,538
2015	38,851,998
2016	36,189,124
2017	15,154,985
2018	14,817,759
2019	10,742,769
Total	\$ 621,717,608

Payments for these services were settled through intercompany accruals and subsequent funding.¹

For additional detail on this transfer, see Exhibit 1R.

¹See **Appendix 3** for the status of our analysis of the intercompany accounts.

2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Based on discussions with Rhodes, various IACs purchase active pharmaceutical ingredients ("API") from Rhodes Tech.¹ These API purchases included, for example, oxycodone hydrochloride, hydrocodone bitartrate, methylphenidate hydrochloride, morphine sulfate, buprenorphine hydrochloride, naloxone hydrochloride, and dronabinol.

From January 1, 2008 to September 15, 2019, various IACs paid Rhodes Tech \$140.7 million for this API. According to Rhodes, the prices at which Rhodes Tech sold API to IACs were determined on the basis of historical market prices.

IAC	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Bard Pharmaceuticals Limited	\$ 3,272,801	\$ 6,136,635	\$ 11,728,748	\$ 13,036,566	\$ 12,050,500	\$ 5,929,003	\$ 11,509,219	\$ 10,433,153	\$ 14,564,696	\$ 19,868,598	\$ 11,363,893	\$ 9,399,676	\$ 129,293,487
The P.F. Laboratories	3,567,370	28,835	652,692	579,415	55,046	-	-	-	-	-	-	-	4,883,358
Napp Pharmaceuticals Limited	1,931,723	-	-	-	-	-	-	-	-	-	-	-	1,931,723
Purdue Pharma (Canada)	171,358	434,200	53,329	214,961	215,135	210,547	53,754	131,508	238,031	129,414	53,244	106,310	2,011,791
Rafa Laboratories Limited	-	20,937	194,089	194,353	290,632	193,385	182,075	198,843	270,422	234,463	231,899	150,782	2,161,880
Modi-Mundi Pharma Pvt. Ltd.	-	-	-	39,189	-	-	-	-	-	-	29,675	-	68,864
Mundipharma Research Limited	-	391,934	-	-	-	-	-	-	-	-	-	-	391,934
Total	\$ 8,943,253	\$7,012,542	\$12,628,858	\$14,064,482	\$12,611,313	\$6,332,936	\$11,745,047	\$10,763,503	\$15,073,149	\$20,232,476	\$11,678,712	\$9,656,767	\$140,743,038

For additional detail on this transfer, see Exhibit 2A.

¹No written agreements exist for these purchases.

2B: Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage product

Based on discussions with Rhodes, Rhodes Pharma provided a small amount of finished dosage products to Mundipharma's Latin America, Asia Pacific and Middle East/Africa ("LAM") region in 2016 and 2017.¹

From 2016 to 2017, Mundipharma paid Rhodes Pharma \$36,000 for finished dosage products. These products were sold at cost plus a [REDACTED] markup.

Product	IAC Purchaser	Date	Quantity	Amount
Oxycodone/APAP 5MG/325MG tablets 100s	Mundipharma Near East GMBH	6/16/2016	[REDACTED]	\$ 1,821
Oxycodone/APAP 5MG/325MG tablets 100s	Mundipharma Near East GMBH	9/28/2016	[REDACTED]	34,140
Total				\$ 35,961

For additional detail on this transfer, see Exhibit 2B.

¹No written agreement exists for these purchases.

2C: Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline

On October 1, 2011, Rhodes Pharma entered into a supply agreement with Mundipharma Laboratories GMBH for theophylline.

From October 1, 2011 to September 15, 2019, Rhodes Pharma paid Mundipharma Laboratories GMBH \$5.3 million for theophylline.

Year	Quantity	Amount
2012		\$ 212,796
2013		506,934
2014		197,148
2015		407,928
2016		1,535,881
2017		518,260
2018		1,368,630
2019		503,510
Total		\$ 5,251,087

For additional detail on this transfer, see Exhibit 2C.

3A: Intercompany transfers between Rhodes Pharma and Purdue for contract manufacturing organization services

Purdue entered into a contract manufacturing agreement to provide CMO services to Rhodes Pharmaceuticals L.P. in 2010, which was restated and/or amended in 2014, 2016, and 2018, to include certain additional products within the scope of this agreement.

From January 1, 2011 to September 15, 2019, Purdue charged Rhodes \$290.6 million for CMO services (inclusive of \$16.3 million in transfer pricing ("TP") adjustments, which adjusted the full factory standard costs incurred down to previously agreed-upon contract prices).

Product	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Morphine Sulfate ER	\$ 17,227,618	\$ 16,262,027	\$ 25,591,951	\$ 19,548,180	\$ 16,702,113	\$ 10,764,115	\$ 9,154,794	\$ 12,588,395	\$ 7,962,369	\$135,801,561
Oxycodone APAP	-	-	-	6,080,578	10,645,036	24,818,928	23,219,950	27,308,720	20,024,302	112,097,512
Oxycodone HCL	488,261	66,257	63,506	5,227,920	3,768,564	7,976,191	9,312,233	8,539,467	13,015,926	48,458,325
Buprenorphine HCL	-	-	-	-	-	-	402,205	2,892,510	2,775,233	6,069,949
MS Contin	-	-	-	-	-	-	462,956	-	395,282	858,238
Dexmethyl HCL	-	-	-	-	-	-	206,288	66,948	155,192	428,428
Hydrocodone/APAP	-	-	-	-	-	-	-	103,096	124,610	227,706
Hydromorphone (Dilaudid)	-	-	-	-	-	-	-	-	2,300,682	2,300,682
Amphetamine	-	-	-	-	-	-	-	-	699,397	699,397
Total before TP adjustments (a)	\$ 17,715,879	\$ 16,328,283	\$ 25,655,457	\$ 30,856,677	\$ 31,115,712	\$ 43,559,234	\$ 42,758,426	\$ 51,499,136	\$ 47,452,993	\$306,941,798
TP adjustments (b)	-	-	(4,697,541)	(2,942,730)	(2,782,019)	(4,362,197)	(1,516,423)	-	-	(16,300,910)
Total (c=a+b)	\$ 17,715,879	\$ 16,328,283	\$ 20,957,916	\$ 27,913,948	\$ 28,333,693	\$ 39,197,037	\$ 41,242,003	\$ 51,499,136	\$ 47,452,993	\$290,640,888

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 3A.

3B: Intercompany transfers between Rhodes and Purdue for allocated shared services functions

Purdue provides Rhodes with IT, benefit plan Administration, and other administrative services. In addition, Purdue provides other services specific to Rhodes such as commercial products manufacturing, distribution, and research and development services (collectively, "Rhodes Shared Services").

From January 1, 2008 to September 15, 2019, Rhodes paid Purdue \$56.6 million for Rhodes Shared Services and Expenses.

Year	Rhodes Shared Services		
	Rhodes Tech	Rhodes Pharma	Total
2008	\$ -	\$ 614,157	\$ 614,157
2009	1,018,502	1,598,670	2,617,172
2010	1,388,732	632,906	2,021,638
2011	1,388,732	1,790,887	3,179,619
2012	1,267,979	2,019,320	3,287,299
2013	1,570,455	1,939,791	3,510,246
2014	1,565,880	2,065,819	3,631,699
2015	1,963,237	3,849,149	5,812,386
2016	1,963,237	5,910,647	7,873,883
2017	1,962,683	7,073,350	9,036,033
2018	1,697,897	7,231,109	8,929,007
2019	1,066,946	5,027,899	6,094,845
Total	\$ 16,854,279	\$ 39,753,703	\$ 56,607,982

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 3B.

3C: Intercompany transfers between Rhodes Pharma and Purdue for licensing generic and branded Dilaudid

In 2010, Purdue granted Rhodes Pharma a license to sell an authorized generic version of Dilaudid. Per discussions with Purdue, this license was not governed by a written agreement and Rhodes did not make any upfront or royalty payments to Purdue for this license.

In 2016, PPLP and Rhodes Pharma entered into an assignment and assumption agreement, effective May 1, 2017, that transferred PPLP's rights in Dilaudid to Rhodes Pharma. The rights transferred under the assignment and assumption agreement included licenses to use the trademarks and patents associated with Dilaudid. (See Exhibit 4I for additional detail regarding this assignment and assumption agreement.)

For additional detail on this transfer, see Exhibit 3C.

3D: Intercompany transfers between Rhodes Pharma and Purdue for all rights to morphine sulfate extended release generic

In 2011, Purdue transferred all rights to sell Morphine Sulfate Extended Release (“MSER”) Generic to Rhodes Pharma. Per discussions with Purdue, this transfer was not governed by a written agreement. Although Rhodes did not make any upfront payments to Purdue for these rights, Purdue and Rhodes entered into an arrangement in 2011 whereby Rhodes paid Purdue █████ of the profits on its 2011 sales of generic MSER. These payments did not continue beyond 2011.

From January 1, 2008 to September 15, 2019, Rhodes paid Purdue \$1.2 million for its portion of the MSER profit share.

Year	MSER Profit
	Share to PPLP
2011	\$ 1,228,841
Total	\$ 1,228,841

Payments for these services were settled through intercompany accruals (e.g. recharges) and subsequent funding.

For additional detail on this transfer, see Exhibit 3D.

3E: Intercompany transfers between Rhodes Pharma and Purdue pursuant to Butrans AG profit-sharing agreement

In July 2017, Rhodes Pharma agreed to sell authorized generics of Butrans on behalf of Purdue. In 2018, Purdue and Rhodes Pharma entered into a formal distribution and profit-sharing agreement governing this relationship.

From 2017 to September 15, 2019, Purdue charged Rhodes Pharma \$77.0 million pursuant to the profit-sharing agreement.

Year	Charges for Profit-Share
2017	\$ 15,568,950
2018	45,764,450
2019	15,672,407
Total	\$ 77,005,807

Payments for this profit-share were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 3E.

3F: Intercompany transfers between Purdue and Rhodes Tech for active pharmaceutical ingredients

Based on discussions with Rhodes, Purdue purchased several types of API from Rhodes Tech, including oxycodone hydrochloride, hydrocodone bitartrate, methylphenidate, morphine sulfate USP, buprenorphine, and naloxone HCI dihydrate.¹ From January 1, 2008 to September 15, 2019, Rhodes Tech charged Purdue \$644.4 million for API. According to Rhodes, the prices at which Rhodes Tech sold API to Purdue were determined on the basis of historical market prices.

Year	Invoice Amounts
2008	\$ 71,259,517
2009	77,620,161
2010	70,564,728
2011	54,140,369
2012	54,369,829
2013	52,971,362
2014	52,215,588
2015	33,726,418
2016	42,913,190
2017	44,207,976
2018	45,410,456
2019	45,042,850
Total	\$644,442,441

Payments for these services were settled through intercompany accruals and subsequent funding.

For additional detail on this transfer, see Exhibit 3F.

¹No written agreement exists for these purchases.

4A: Transfer from Purdue of its equity interest in Coventry Technologies L.P. to PRA L.P. in 2008 at a valuation of \$52.3 million

On January 1, 2008, PPLP and PLP Associates Holdings L.P. ("PLPAH")¹ entered into an assignment and assumption agreement under which PPLP was authorized and directed to distribute its 100% interest in Coventry Technologies L.P. ("Coventry").² The transfer of ownership was executed at its book value of \$52.3 million. This transfer was one of a series of transactions that established Rhodes Tech as a stand-alone API supplier and Rhodes Pharma as a stand-alone generics-focused pharmaceutical business.

2008	Book Value
Partner's capital & retained earnings	\$ 51,506,000
Accumulated other comprehensive income	822,000
Total	\$ 52,328,000

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4A.

¹In 2010, PLPAH was replaced by Purdue Holdings L.P. (now known as PRA L.P.) as the direct parent entity to PPLP.

²From January 1, 2008 to May 28, 2019, Coventry was the parent entity to Rhodes Tech and Rhodes Pharma.

4B: Transfer from Purdue of its stock in Infinity Pharmaceuticals, Inc. to PRA L.P. in 2008, 2009 and 2013 at a valuation of \$263.1 million

In 2008, Purdue transferred 4 million shares of Infinity Pharmaceuticals Inc. (“Infinity”) common stock to PRA L.P. at a valuation of \$21.2 million based on the market price at the time.

In 2009, Purdue transferred an additional 2 million shares of Infinity common stock to PRA L.P. at a valuation of \$11.8 million based on the market price at the time.

In 2013, Purdue transferred an additional 5,416,565 shares of Infinity to PRA L.P. at a valuation of \$230.1 million based on the market price at the time.

Year	Number of	
	Shares	Transfer Amount
2008	4,000,000	\$ 21,160,000
2009	2,000,000	11,830,000
2013	5,416,565	230,095,681
Total	11,416,565	\$ 263,085,681

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4B.

4C: Transfer from Purdue of its equity interest in Millsaw Realty L.P. to PRA L.P. in 2009 at a valuation of \$7.4 million

On January 1, 2009, PPLP and PLPAH entered into an assignment and assumption agreement under which PPLP was authorized and directed to distribute its 100% interest in Millsaw Realty L.P. ("Millsaw"). Per the 2009 audited financial statements, Purdue transferred its ownership to PRA L.P. at its book value of \$7.4 million and recognized it as the difference between balance sheet retained earnings and cash/cash equivalents per Purdue.

	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Partners' Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
	(In thousands)						
Investment distributions:							
Millsaw Realty L.P.	-	-	-	(7,412)	-	-	(7,412)

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4C.

Note: The Cash Transfers of Value Report references a \$30 million cash distribution made by Millsaw Realty L.P. to Beacon Company ("Beacon") and Rosebay Medical Company L.P. ("Rosebay") in 2010. This cash distribution was not included in Purdue's combined audited financial statements or the October 19, 2018 MDL Presentation as Millsaw Realty L.P. was not a subsidiary of Purdue at the time the cash distribution was made.

4D: Transfer from Purdue of its stock in Kolttan Pharmaceuticals to PRA L.P. in 2009 and 2014 at a valuation of \$13.0 million and \$2.2 million

In September 2009, Purdue transferred its ownership of Kolttan Pharmaceuticals (“Kolttan”) Series A Convertible Preferred Stock to PRA L.P. at a valuation of \$12.95 million.

In July 2014, Purdue transferred its ownership of Kolttan Series D Shares to PRA L.P. at a valuation of \$2.05 million, plus a cash payment of \$10,175.

In December 2014, Purdue transferred its ownership of Kolttan common stock to PRA L.P. at a valuation of \$110,080, plus a cash payment of \$547.

Year	Type of Distribution	Transfer Amount
2009	Series A Shares	\$ 12,950,000
2014	Series D Shares	2,050,000
2014	Common Stock	110,080
2014	Cash	10,722
Total		\$ 15,120,802

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4D.

4E: Transfer from Purdue of its stock in Novelos Therapeutics, Inc. to PRA L.P. in 2009 at a valuation of \$23.1 million

In March 2009, Purdue transferred its ownership of 15,384,615 shares of common stock in Novelos Therapeutics, Inc. ("Novelos") to PRA L.P. at a valuation of \$10 million (i.e., at the price Purdue paid for the common stock at \$0.65 per share).

On August 25, 2009, Purdue transferred its ownership of an additional 13,636,364 shares of common stock to PRA L.P. at a valuation of \$13.1 million based on an internal Purdue fair market value analysis.

Year	Type of Stock	Transfer Amount	
2009	Common	\$	10,000,000
2009	Common		13,140,097
Total		\$	23,140,097

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4E.

4F: Transfer from Purdue of its equity interest in Lucien Holdings S.ar.l. to PRA L.P. in 2010 at a valuation of negative \$0.5 million

On April 30, 2010, PPLP and Purdue Holdings L.P. (now known as PRA L.P.) entered into an assignment and assumption agreement under which PPLP was authorized and directed to distribute its 100% interest in Lucien Holdings S.ar.l. ("Lucien"). Per Purdue's audited financial statements and internal analysis, Purdue transferred its ownership of Lucien at its book value of negative \$0.5 million.

2010	Book Value
Partner's capital - End of Period	\$ (542,000)

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4F.

4G: Transfer from Purdue of its equity interest in New Suffolk Holdings LLP to PRA L.P. in 2010 at a valuation of \$32.8 million

On April 30, 2010, PPLP and Purdue Holdings L.P. (now known as PRA L.P.) entered into an assignment and assumption agreement under which PPLP was authorized and directed to distribute its 100% interest in New Suffolk Holdings LLP ("NSH"). According to Purdue's audited financial statements and an internal analysis of this transfer conducted in 2010, Purdue recorded this transfer in its books and records at book value of \$32.8 million.

2010	Book Value
Partner's capital - End of Period	\$ 32,761,000

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4G.

4H: Transfer from Purdue of its rights to royalty payments from foreign IACs on non-ADF OxyContin to PRA L.P. in 2017

On January 1, 2017, PPLP and Purdue Holdings L.P. (now known as PRA L.P.) entered into multiple assignment and assumption agreements pursuant to which PPLP transferred all of its rights, title and interest in non-ADF OxyContin under the applicable foreign license agreements with ex-US IACs to Purdue Holdings L.P.

Regions Covered in Agreements			
Arab States	France	Lebanon	South Africa
Austria	Germany	Netherlands	Spain
Belgium	Hong Kong	New Zealand	Sweden
Cen. & East Europe	Iceland	Norway	Switzerland
China	Ireland	Philippines	United Kingdom
Cyprus	Italy	Poland	
Denmark	Jordan	Saudi Arabia	
Finland	Kuwait	Singapore	

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4H.

4I: Transfer from Purdue of all rights to Dilaudid to PRA L.P. in May 2017 at a valuation of \$17 million

On October 1, 2016, PPLP and Rhodes Pharma entered into an assignment and assumption agreement under which Purdue's rights, title and interest in Dilaudid and MS Contin were transferred to Rhodes Pharma pursuant to a series of distributions from Purdue to its shareholders (starting with PRA L.P., and up to Beacon and Rosebay), which, in turn, contributed these assets back down to Rhodes Pharma through Rhodes Pharma's then-parent entity, Coventry. This transfer became effective on May 1, 2017. Based on Purdue's audited financial statements and internal analysis, the rights to Dilaudid were transferred at its book value of \$17 million.

2017	Book Value
Dilaudid Product Rights	\$ 41,435,851
Accumulated Ammortization	(24,469,360)
Total	\$ 16,966,491

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4I.

4J: Transfer from Purdue of all rights to MS Contin to PRA L.P. in 2017

On October 1, 2016, PPLP and Rhodes Pharma entered into an assignment and assumption agreement under which Purdue's rights, title and interest in Dilaudid and MS Contin were transferred to Rhodes Pharma pursuant to a series of distributions from Purdue to its shareholders (starting with PRA L.P., and up to Beacon and Rosebay) which, in turn, contributed these assets back down to Rhodes Pharma through Rhodes Pharma's then-parent entity, Coventry. That transfer was made in May 2017. Per the audited financial statements, the rights to MS Contin were transferred at a valuation of \$0 as the value of the transferred rights for Dilaudid accounted for the full value of the combined transfer.

2017	Book Value
MS Contin Product Rights	\$ -

Purdue did not receive any consideration for this transfer.

For additional detail on this transfer, see Exhibit 4J.

AlixPartners

IV. Exhibits



Exhibit 1 – Intercompany Transfers Between Purdue and IACs

IV. Exhibit 1: Intercompany transfers between Purdue and IACs

- A. Intercompany transfers between Purdue to Mundipharma International Limited (USA) for manufacturing services support
- B. Intercompany transfers between Purdue to One Stamford Realty L.P. for office space at One Stamford Forum
- C. Intercompany transfers between Purdue to Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services
- D. Intercompany transfers between Purdue to Purdue Pharma Technologies Inc. for finished products from 3rd parties
- E. Intercompany transfers between Purdue to The P.F. Laboratories Inc. for contract manufacturing organization services
- F. Intercompany transfers between Purdue to The Terramar Foundation, Inc. for office space
- G. Intercompany transfers between Purdue to TXP Services Inc. for financial and tax services
- H. Intercompany transfers between Purdue to Mundipharma Research Limited for R&D services
- I. Intercompany transfers between Purdue to Mundipharma EDO GmbH for R&D services

IV. Exhibit 1: Intercompany transfers between Purdue and IACs (cont.)

- J. Intercompany transfers between Purdue to Mundipharma UK for consulting and legal services
- K. Intercompany transfers between Purdue to Mundipharma A.G. to manufacture and sell MS Contin in the United States
- L. Intercompany transfers between Purdue to Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot
- M. Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services
- N. Transfer of the Adhansia assets from Purdue Pharma (Canada) to Purdue in 2018
- O. Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan
- P. Intercompany transfers between various IACs (E.R.G. Realty Inc., Mundipharma International Limited (USA), One Stamford Realty L.P., Pharma Associates L.P., and Purdue Pharma Technologies Inc.) and Purdue for accounting, HR, and other similar services
- Q. Intercompany transfers between foreign IACs and Purdue for finished products
- R. Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

On January 1, 2014, Purdue entered into a services agreement with MIL USA, the service provider. The agreement is generally for manufacturing services. While the agreement references Schedule I of the agreement (which lists the specific services to be provided), Schedule I could not be found in connection with this analysis. On August 3, 2018, Purdue also entered into a service agreement with MITOL.

SERVICES AGREEMENT

1. **MUNDIPHARMA INTERNATIONAL LIMITED**, a company incorporated in Delaware, whose registered office is at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership, whose principal place of business is at One Stamford Forum, Stamford, Connecticut 06901 ("**Customer**").

MUNDIPHARMA INTERNATIONAL LIMITED (USA)

- (xv) "Services" means the services to be provided by Service Provider pursuant to this Agreement as the same are more particularly described in Schedule 1 hereto together with any other incidental services which may be agreed between Customer and Service Provider;

– AND –

PURDUE PHARMA L.P.

2. Range of Services
 - (a) Service Provider will provide such of the Services as may be required by Customer from time to time.
 - (b) Nothing in this Agreement shall prevent Customer from obtaining all or part of the Services from any other service provider or resource.

EFFECTIVE: 1ST JANUARY 2014

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

According to the services agreement, Purdue pays for the cost of services to MIL USA plus a markup of 10%. The same arrangement is stipulated under the service agreement with MITOL.

6. Price and Payment

- (a) With respect to the Initial Term and any subsequent term of this Agreement, as applicable, the price for the Services provided hereunder from time to time shall be the cost to Service Provider of providing the Services plus a service fee in the amount of ten percent (10%) of such cost (the "Estimated Payments"). The Estimated Payments for the Initial Term are set forth in Schedule 2. The Estimated Payments for any subsequent term shall be agreed upon by the Parties on or before December 31 of the Year prior to each such subsequent term. As far as practical, Service Provider will arrange for the recovery of the travel, subsistence and incidental expenses it incurs directly through Customer.
- (b) Customer will be invoiced for the Services quarterly in advance and will pay the invoice within thirty (30) days, with payments due in amounts as set forth in Schedule 2 (as the same may be amended from time to time).
- (c) Unless otherwise agreed each quarterly invoice will be for an amount equal to one quarter of the Estimated Payments. Service Provider will provide a mid-Year update to the Estimated Payments and will adjust each quarterly invoice to reflect such revised estimates.

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

Since January 1, 2014 (the date of the agreement), Purdue has paid \$5.5 million in costs and markups to MIL USA, and since January 2018 Purdue has paid \$2.4 million to MITOL. The total paid to both MIL USA and MITOL since 2014 totals \$7.9 million.

Year	MIL USA	MITOL	Total
2016	\$ 2,319,638	\$ -	\$ 2,319,638
2017	1,697,519	-	1,697,519
2018	1,433,480	1,179,121	2,612,601
2019	37,168	1,231,997	1,269,165
Total	\$ 5,487,805	\$ 2,411,118	\$ 7,898,923

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

According to MIL USA's accounting records in SAP, Purdue has paid \$5.5 million to MIL USA (SAP company code 543) for manufacturing services support through G/L account 101016 (Accounts Receivable), as illustrated below.

Per discussions with Purdue, such services did not begin until 2015, the first payment on these services occurred in 2016. Further, while the contract called for quarterly payments in advance, the parties did not always adhere to this provision.

G/L Account Line Item Display

</

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

According to MITOL's accounting records in SAP, Purdue has paid \$2.4 million to MITOL (SAP company code 543) for manufacturing services support through G/L account 101016 (Accounts Receivable), as illustrated below.

G/L Account		101016	Accounts Receivable (Manual A/R Billings)								
Company Code		544									
St	DocumentNo	Type	Doc. Date	Period	Pstng Date	Account	CoCd	Amount in local cur.	Profit Ctr	Cost Ctr	Reference
<input type="checkbox"/>	1400000000	DZ	01/10/2018	1	01/11/2018	101016	544	357,186.00-			PD WT 1/10/18
<input type="checkbox"/>	1400000003	DZ	06/28/2018	6	06/29/2018	101016	544	466,132.00-			PD WT 6/28/18
<input type="checkbox"/>	1400000004	DZ	09/10/2018	9	09/10/2018	101016	544	355,803.00-			PD WT 9/7/18
<input type="checkbox"/>	1400000006	DZ	01/15/2019	1	01/16/2019	101016	544	739,501.00-			PD WT 1/15/19
<input type="checkbox"/>	1400000008	DZ	04/05/2019	4	04/05/2019	101016	544	492,496.00-			PD WT 4/5/19
*								2,411,118.00-			

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

The calculation of the amount due from Purdue to MIL USA is tracked via spreadsheet by Purdue (2015 is illustrated below with the payment amount in yellow). This payment reconciles to the individual payment line item in SAP on slide 66.

Mundipharma International Limited (USA)				
Company 543				
2015 Billing to PPLP				
	BILLED	BILLED		
	Q2 - Q3 2015	Q4 2015	Total 2015	
P&L				
Salary, Bonus and Benefits				
Salary and cash in lieu of car	\$ 167,600	\$ 159,457	\$ 327,057	4th Qtr includes N.D., N.G. and D.L.
Taxes (ER)	7,084	5,124	12,208	
401(K) match	0	1,531	1,531	
Health Benefits, Life Insurance, 401k enhancement etc	12,916	15,000	27,916	
2015 LTRP Expense	0	6,345	6,345	
2015 LTI (New)		125,000	125,000	
SSP	16,760	8,380	25,140	
Bonus	0	0	0	
Subtotal Salary, Bonus, and Benefits	\$ 204,360	\$ 320,837	\$ 525,197	
Other Costs				
Travel Costs	\$ 43,070	\$ 25,000	\$ 68,070	
Accounting and Payroll Services Provided by PPLP	1,650	825	2,475	Recharged at cost plus 10% from PPLP
TXP (tax preparation service)	87	44	131	Recharged at cost plus 10% from TXP
Bank service charge	44	22	66	
Ceridian Processing Fees	0	0	0	
Reimbursement of tax payments	0	0	0	
Rent Exp	750	375	1,125	
LTRP expense			0	
One time relocation costs	0	0	0	
Other Costs	2,670		2,670	
True up for actual/ prior year expenses	0	0	0	
Subtotal Other Costs	\$ 48,271	\$ 26,266	\$ 74,537	
Total expense	\$ 252,631	\$ 347,103	\$ 599,734	
Recharge to PPLP:				
- Salary, Bonus and Benefits recharged at Cost plus 7.5%	(219,687)	(344,900)	(564,587)	
- Other Costs invoiced with no mark-up	(48,271)	(26,266)	(74,537)	
Total recharge	\$ (267,958)	\$ (371,165)	\$ (639,123)	
Net Income	\$ (15,327)	\$ (24,063)	\$ (39,390)	

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

The calculation of the amount due under the agreement with MIL USA is tracked via spreadsheet by Purdue (2017 illustrated below with payment amounts in yellow). These payments reconcile to the individual payment line items in SAP on slide 66. Despite the 10% stipulated in the agreement, only a 7.5% markup was applied to salary-related expenses (salary, bonus, long-term incentives, retention, benefits, etc.).

Mundipharma International Limited (USA)					
Company 543					
2017 Billing to PPLP					
	BILLED Q1 2017	BILLED Q2 2017	BILLED Q3 2017	BILLED Q4 2017	Total 2017
P&L					
Salary, Bonus and Benefits					
Salary and cash in lieu of car	\$ 170,233	\$ 198,605	\$ 175,044	\$ 662,910	\$ 1,206,791
Taxes (ER)	12,703	8,813	3,164	10,350	35,030
Taxes (ER) - Add'l charge for true up due to LTI pymt in 3/16			0	0	-
401(K) match	3,669	4,281	5,077	3,173	16,200
Health Benefits, Life Insurance, 401k enhancement etc	28,500	28,500	28,500	28,500	114,000
2015 - 2016 LTRP Expense (Billed in Dec)	0	0	0	0	-
2015- 2016 LTI (New- Billed in Dec)			0	0	-
SSP	0	3,865	8,040	50,884	62,789
SSP- Add'l charge for true up due to LTI pymt in 3/16			0	0	-
Bonus (Billed when paid)	0		0		-
True up for actual/ Jan - June current expenses			36,507	0	36,507
Subtotal Salary, Bonus, and Benefits	\$ 215,105	\$ 244,064	\$ 256,332	\$ 755,817	\$ 1,471,317
Other Costs					
Travel Costs	\$ 41,750	\$ 30,000	\$ 30,000	\$ 30,000	\$ 131,750
Accounting and Payroll Services Provided by PPLP	1,320	1,320	1,320	1,320	5,280
TXP (tax preparation service)	90	90	90	90	360
Consultant Fee	1,875	1,875	1,875	80,000	85,625
Bank service charge	75	75	75	75	300
Ceridian Processing Fees	350	350	350	350	1,400
Reimbursement of tax payments	0		0	0	-
Rent Exp	1,080	1,080	1,080	1,080	4,320
One time relocation costs	0		0	0	-
Fleet Related Expenses	3,750	3,750	3,750	3,750	15,000
Seminars & Symposia	1,313	1,313	1,400	1,400	5,426
Other Costs	479	479	200	200	1,359
True up for actual/ Jan - June current expenses			65,485		65,485
True up for actual/ prior year expenses		25,556	0	0	346,080
Subtotal Other Costs	\$ 372,606	\$ 65,888	\$ 105,625	\$ 118,265	\$ 662,385
Total expense	\$ 587,711	\$ 309,952	\$ 361,957	\$ 874,082	\$ 2,133,702
Recharge to PPLP:					
- Salary, Bonus and Benefits recharged at Cost plus 7.5%	(231,238)	(262,369)	(275,557)	(812,503)	(1,581,666)
- Other Costs invoiced with no mark-up	(372,606)	(65,888)	(105,625)	(118,265)	(662,385)
Total recharge	\$ (603,844)	\$ (328,257)	\$ (381,182)	\$ (930,768)	\$ (2,244,051)
Net Income	\$ (16,133)	\$ (18,305)	\$ (19,225)	\$ (56,686)	\$ (110,349)

4th Qtr includes N.D., A.G., P.K. and D.L.

Recharged at cost plus 10% from PPLP

Recharged at cost plus 10% from TXP

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

Below is an example of a cash payment in 2018 (for 4th quarter 2017 services rendered) which was recognized as follows in Mundipharma International Limited (USA)'s accounting records. MITOL also recognized cash payments in a similar manner to MIL USA.

Account Number	Account Description	DR	CR
100010	Cash Concentration	\$ 930,768	
101040	A/R Clearing Account		\$ (930,768)
101040	A/R Clearing Account	\$ 930,768	
101016	PPLP A/R Customer Account (Customer # 1231)		\$ (930,768)

Exhibit 1A: Intercompany transfers between Purdue and Mundipharma International Limited (USA) for manufacturing services support

These entries appear in SAP as follows:

Document Overview - Display

Doc.Type : SA (G/L account document) Normal document
 Doc. Number 100001141 Company Code 543 Fiscal Year 2018
 Doc. Date 15.01.2018 Posting Date 14.01.2018 Period 01
 Calculate Tax ☐
 Ref.Doc. CWS
 Doc. Currency USD
 Doc. Hdr Text CTW543 01082018-01142018

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	100010	Cash Concentration		GEN			930.768,00	INVOICE MI-127 QUARTERLY SERVICES CHARGE FOR 4Q17
2	40	100010	Cash Concentration		GEN			950.753,00	78658368 MUNDIPHARMA INTERNATIONAL TECHNICALCAMERI
3	50	101040	A/R Clearing (Trade)		GEN			930.768,00-	INVOICE MI-127 QUARTERLY SERVICES CHARGE FOR 4Q17
4	50	101045	A/R Clring (NonTrade)		GEN			950.753,00-	78658368 MUNDIPHARMA INTERNATIONAL TECHNICALCAMERI

Document Overview - Display

Doc.Type : DZ (Customer payment) Normal document
 Doc. Number 1400000033 Company Code 543 Fiscal Year 2018
 Doc. Date 09.01.2018 Posting Date 10.01.2018 Period 01
 Calculate Tax ☐
 Ref.Doc. PD WT 1/9/18
 Doc. Currency USD
 Doc. Hdr Text #930,768.00 MI-127

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	101040	A/R Clearing (Trade)		GEN			930.768,00	
2	15	1231	PURDUE PHARMA LP					930.768,00-	

Display Document: Line Item 002

Customer 1231 PURDUE PHARMA LP G/L Acc 101016
 CoCode 543 ONE STAMFORD FORUM
 Mundipharma Int'l. Ltd. STAMFORD Doc. No. 1400000033
 Line Item 2 / Incoming payment / 15
 Amount 930.768,00 USD

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

On April 6, 2006, Purdue entered into a lease agreement with One Stamford Realty L.P., the landlord, for the following space at One Stamford Forum (the "OSF Lease"):

LEASE, dated as of April 6, 2006 (as may be amended, modified or supplemented from time to time, this "Lease"), between ONE STAMFORD REALTY L.P., a Delaware limited partnership, whose address is One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901 ("Landlord"), and PURDUE PHARMA L.P., a Delaware limited partnership, whose address is One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901 ("Tenant");

W I T N E S S E T H

WHEREAS, Landlord is willing to lease to Tenant and Tenant is willing to hire from Landlord, on the terms and conditions hereinafter set forth, certain space in the office building located at One Stamford Forum, Stamford, Connecticut (the "Building") on the land more particularly described in Exhibit A (the "Land"); the Land and the Building are collectively called the "Project";

NOW, THEREFORE, Landlord and Tenant agree as follows:

1.01 Demise. (a) Landlord hereby leases to Tenant and Tenant hereby hires from Landlord, subject to the terms and conditions of this Lease, the P-1 floor (including but not limited to the data centers), the P-2 floor, the P-3 floor, the plaza floor, the 4th floor, the 5th floor, the 6th floor, the 7th floor, the 8th floor, the 9th and 10th floors of the Building (collectively, the "Premises"), substantially as shown on the plans thereof attached hereto as Exhibit B.

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

According to the lease agreement, Purdue agreed to pay the following rent by floor:

Exhibit D

FIXED RENT

A. In respect of the Data Center:

From January 1, 2006 through December 31, 2020 $\$75 \times 11,696 =$ \$73,100 per month

B. In respect of the P-1 and P-2 Floors (together):

From January 1, 2006 through December 31, 2010 $\$15 \times 8,078 =$ \$10,097.50 per month

From January 1, 2011 through December 31, 2015 $\$16.50 \times 8,078 =$ \$11,107.25 per month

From January 1, 2016 through December 31, 2020 $\$18 \times 8,078 =$ \$12,117.00 per month

C. In respect of the P-3 Floor

From January 1, 2006 through December 31, 2020 $\$20 \times 34,441 =$ \$57,401.66 per month

D. In respect of the Plaza Floor:

From January 1, 2006 through December 31, 2008 $\$39 \times 18,157 =$ \$59,010.25 per month

From January 1, 2009 through December 31, 2010 $\$40 \times 18,157 =$ \$60,523.33 per month

From January 1, 2011 through December 31, 2015 $\$41 \times 18,157 =$ \$62,036.42 per month

From January 1, 2016 through December 31, 2020 $\$43 \times 18,157 =$ \$65,062.58 per month

E. In respect of the 6th Floor:

From January 1, 2006 through December 31, 2008 $\$39 \times 53,482 =$ \$173,816.50 per month

From January 1, 2009 through January 31, 2009 $\$40 \times 53,482 =$ \$178,273.33 per month

F. In respect of the 7th Floor:

From January 1, 2006 through December 31, 2008 $\$39 \times 50,670 =$ \$164,677.50 per month

From January 1, 2009 through January 31, 2009 $\$40 \times 50,670 =$ \$168,900.00 per month

G. In respect of the 8th Floor:

From January 1, 2006 through December 31, 2008 $\$39 \times 61,377 =$ \$199,475.25 per month

From January 1, 2009 through December 31, 2010 $\$40 \times 61,377 =$ \$204,590.00 per month

From January 1, 2011 through December 31, 2015 $\$41 \times 61,377 =$ \$209,704.75 per month

From January 1, 2016 through December 31, 2020 $\$43 \times 61,377 =$ \$219,934.25 per month

H. In respect of the 9th and 10th Floors (together):

From January 1, 2006 through December 31, 2007 $\$45 \times 94,643 =$ \$354,911.25 per month

From January 1, 2008 through December 31, 2008 $\$46 \times 94,643 =$ \$362,798.16 per month

From January 1, 2009 through December 31, 2010 $\$47 \times 94,643 =$ \$370,685.08 per month

From January 1, 2011 through December 31, 2015 $\$48 \times 94,643 =$ \$378,572.00 per month

From January 1, 2016 through December 31, 2020 $\$50 \times 94,643 =$ \$394,345.83 per month

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

According to the lease agreement, Purdue agreed to pay electric, tax and operating expenses.

2.03 Additional Rent. “Additional Rent” means Tax Payments, Operating Payments and all other sums of money at any time payable by Tenant under this Lease, all of which Additional Rent shall be deemed to be rent.

2.07 Electric Charges. (a) Tenant’s demand for, and consumption of, electricity for the Premises shall be determined by meter or meters installed by Landlord on or before the Commencement Date. Tenant shall pay for electric consumption within 30 days after rendition of a bill therefor (but in no event more than 15 days before Landlord’s payment for the applicable period is due to the public utility), which bill shall reflect the aggregate charge for electricity for the Premises, as determined by or on behalf of Landlord separately for each meter.

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

On May 3, 2006, UBS agreed to lease the 6th, 7th and 8th floors at One Stamford Forum (the "UBS Sublease") which reduced Purdue's contractual rental payments owed to One Stamford Realty.



UBS AG
Stamford Branch
677 Washington Boulevard
Stamford, CT 06901
Telephone 203 719-3000
www.ubs.com

May 3, 2006

By Overnight Courier

One Stamford Realty L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, Connecticut 06901
Attention: Edward B. Mahony

Re: One Stamford Forum, Stamford, Connecticut

Dear Mr. Mahony:

Reference is made to the Lease, dated as of December 30, 2005, between One Stamford Realty L.P., as landlord ("Landlord"), and UBS AG, acting through its Stamford Branch, as tenant ("UBS"), with respect to portions of the building located at One Stamford Forum, Stamford, Connecticut (the "Lease"). All capitalized terms used but not otherwise defined in this letter shall have the meanings ascribed to them in the Lease.

This letter constitutes an "8th Floor Election Notice" under Section 1.01(a) of the Lease. UBS hereby notifies Landlord that UBS desires to include the 8th floor of the Building in the Premises initially demised under the Lease. As a result thereof:

1. Phase 3 of the Premises shall consist of the 7th and 8th floors of the Building with a Scheduled Commencement Date of April 1, 2008.
2. Phase 4 of the Premises shall consist of the 6th floor of the Building with a Scheduled Commencement Date of May 4, 2007.

Very truly yours,
UBS AG, acting through its Stamford Branch

By

[Redacted Signature]
Title: Managing Director

By

[Redacted Signature]
Title: Managing Director

Cc: One Stamford Realty L.P. (By overnight courier)
One Stamford Forum
201 Tresser Boulevard
Stamford, Connecticut 06901
Attention: Howard R. Udell

P:\One Stamford Forum 8th Floor Election Notice 05-03-06.doc

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

Effective February 28, 2008 and January 26, 2009, UBS began paying rent on the 6th, 7th and 8th floors. Pursuant to UBS's "8th Floor Election Notice" Letter (on the previous slide and excerpted below), these dates are equal to 300 days after the Commencement Date for each respective "Phase."

(iii) "Phase 3 Rent Commencement Date" means the later of (A) February 1, 2009 and (B) the date that is 300 days after the Commencement Date for Phase 3.

(iv) "Phase 4 Rent Commencement Date" means the date that is 300 days after the Commencement Date for Phase 4.

This letter constitutes an "8th Floor Election Notice" under Section 1.01(a) of the Lease. UBS hereby notifies Landlord that UBS desires to include the 8th floor of the Building in the Premises initially demised under the Lease. As a result thereof:

1. Phase 3 of the Premises shall consist of the 7th and 8th floors of the Building with a Scheduled Commencement Date of April 1, 2008.
2. Phase 4 of the Premises shall consist of the 6th floor of the Building with a Scheduled Commencement Date of May 4, 2007.

Very truly yours,
UBS AG, acting through its Stamford Branch

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

Effective July 1, 2018, Purdue entered into a services agreement with One Stamford Realty L.P. for additional facilities and administrative services.

Services Agreement

Facilities and Administrative Services

One Stamford Realty L.P. (“OSR”) and Purdue Pharma LP (“PPLP”)

This Services Agreement (“Services Agreement”) is entered into by and between OSR and PPLP and shall be effective as of July 1, 2018 (“Services Agreement Effective Date”).

RECITALS

WHEREAS, OSR has provided and continues to provide certain services to PPLP and its subsidiaries related to the One Stamford Forum property (as defined in the Lease) pursuant to that certain Lease dated as of April 6, 2006 between OSR and PPLP (as amended) (the “Lease”) and PPLP compensates OSR for those services in accordance with the provisions of the Lease; and

WHEREAS, PPLP has requested that OSR provide certain additional facilities and administrative services (collectively, the “Services”) to PPLP and its subsidiaries as set forth in this Services Agreement and on Exhibit 1 attached hereto and made a part hereof.

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

According to the services agreement, Purdue agreed to pay a fixed fee as set forth below.

Compensation: OSR's fee for services performed under this Services Agreement shall be comprised of an annual fixed fee (the "Fixed Fee") representing the amount payable for "Fixed Fee Services" (as set forth in Exhibit 1) provided in a given calendar year. The Fixed Fee will be billed quarterly in advance in equal installments and paid 15 days before the start of the quarter. The Fixed Fee for 2019 is [REDACTED] and the quarterly billing for 2019 is [REDACTED]

The Fixed Fee in 2020 shall be equal to the Fixed Fee for 2019 year increased by [REDACTED] provided (i) PPLP is still a tenant in One Stamford Forum and (ii) there have been no material changes at the senior staff level at OSR. In the event the conditions of items (i) or (ii) change in 2020 or before, the parties will renegotiate the Fixed Fee for 2020 and execute a written amendment to this Services Agreement detailing the revised services to be performed and the cost for such services. The Fixed Fee in 2021 and thereafter will be determined as set forth below. For the avoidance of doubt, the fee for services from Services Agreement Effective Date to December 31, 2018 have been fully paid by PPLP and OSR.

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

From January 1, 2008 to September 15, 2019, Purdue paid \$105.0 million¹ to One Stamford Realty L.P. pursuant to the OSF Lease and Services Agreement (net of the UBS Sublease).

Year	Rent	Electric	Real Estate Tax	Operating Expenses	Administrative Services Fees	Total Payments
2008	\$ 11,232,286	\$ 629,749	\$ 467,192	\$ 177,957	n/a	\$ 12,507,183
2009	6,929,840	683,394	413,073	181,625	n/a	8,207,931
2010	6,872,101	841,979	513,691	306,791	n/a	8,534,562
2011	6,986,608	734,650	530,019	284,191	n/a	8,535,468
2012	6,986,608	710,058	549,499	250,043	n/a	8,496,208
2013	6,986,608	724,127	495,018	276,042	n/a	8,481,795
2014	6,986,608	580,193	442,825	163,787	n/a	8,173,413
2015	7,006,418	507,245	466,461	252,032	n/a	8,232,156
2016	7,224,325	500,637	489,139	350,689	n/a	8,564,790
2017	7,224,325	522,069	513,254	301,303	n/a	8,560,951
2018	7,224,325	579,368	556,504	394,044	548,619	9,302,860
2019	5,418,244	477,244	499,575	378,730	658,957	7,432,750
Total	\$ 87,078,294	\$ 7,490,713	\$ 5,936,250	\$ 3,317,234	\$ 1,207,576	\$ 105,030,067

¹Electric, real estate tax, and administrative and operating expenses are based on a TXP analysis. AlixPartners needs to confirm the amounts with TXP.

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

According to PPLP's accounting records in SAP, the annual rent payments were recorded on PPLP's books (SAP company code 208) through G/L account 130160 (Deposits on Long Term Assets). The rent payments for 2008 and 2018 are illustrated below.

CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	208	1900035702	21.01.2008	21.01.2008	1	2008/01	KR	12108	130160	GEN	MONTHLY RENT	1.089.533,69	USD	
<input type="checkbox"/>	208	1900037035	25.02.2008	25.02.2008	2	2008/02	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900038205	25.03.2008	25.03.2008	3	2008/03	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900039526	25.04.2008	25.04.2008	4	2008/04	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900040869	25.05.2008	25.05.2008	5	2008/05	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900042342	25.06.2008	25.06.2008	6	2008/06	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900043693	25.07.2008	25.07.2008	7	2008/07	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900045136	25.08.2008	25.08.2008	8	2008/08	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900046599	25.09.2008	25.09.2008	9	2008/09	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900047923	25.10.2008	25.10.2008	10	2008/10	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900049148	25.11.2008	25.11.2008	11	2008/11	KR	MONTHLY RENT CSR	130160	GEN	MONTHLY RENT FOR YEAR 2008	926.560,32	USD	
<input type="checkbox"/>	208	1900050497	18.12.2008	16.12.2008	12	2008/12	KR	121608	130160	GEN	RENT FOR JANUARY 2008	877.148,45	USD	
<input type="checkbox"/>												11.232.285,54	USD	

G/L Account Line Item Display

<

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

Cash rent payments to One Stamford Realty L.P. were recognized as follows in PPLP's accounting records (January 2009 rent, payable in December 2008 is illustrated below):

Account Number	Account Description	DR	CR
130160	Deposits on Long Term Assets	\$ 877,148	
200000	Accounts Payable		\$ (877,148)
200000	Accounts Payable	\$ 877,148	
100010	Cash Concentration		\$ (877,148)

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

These entries appear in PPLP's accounting records in SAP as follows (January 2009 rent, payable in December 2008 is illustrated below):

Doc.Type : KR (Vendor invoice) Normal document

Doc. Number

1900050497

Company Code

208

Fiscal Year

2008

Doc. Date

16.12.2008

Posting Date

18.12.2008

Period

12

Calculate Tax

☒

Ref.Doc.

121608

Doc. Currency

USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1004140	ONE STAMFORD REALTY		GEN		U1	877.148,45-	RENT FOR JANUARY 2008
2	40	130160	Deposits On Assets		GEN			877.148,45	RENT FOR JANUARY 2008

Doc.Type : KZ (Vendor payment) Normal document

Doc. Number

1500002537

Company Code

208

Fiscal Year

2008

Doc. Date

31.12.2008

Posting Date

31.12.2008

Period

12

Calculate Tax

☐

Ref.Doc.

WIRE TRANSFER

Doc. Currency

USD

Note: text box above incorrectly states "2008" instead of "2009"

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			877.148,45-	
2	25	1004140	ONE STAMFORD REALTY		GEN			877.148,45	

Note: text box above incorrectly states "2008" instead of "2009"

Display Document: Line Item 002

Additional Data Withholding Tax Data

Vendor 1004140 ONE STAMFORD REALTY LP G/L Acc 200000

Company Code 208 201 TRESSER BLVD

Purdue Pharma L.P. STAMFORD Doc. no. 1500002537

Line Item 2 / Outgoing payment / 25

Amount 877.148,45 USD

Exhibit 1B: Intercompany transfers between Purdue and One Stamford Realty L.P. for office space at One Stamford Forum

These entries appear in PPLP's accounting records in SAP as follows (January 2019 rent, payable in December 2018 is illustrated below):

Document Overview - Display

Doc.Type : KR (Vendor invoice) Normal document
 Doc. Number 1900174305 Company Code 208 Fiscal Year 2018
 Doc. Date 20.12.2018 Posting Date 20.12.2018 Period 12
 Calculate Tax ☐
 Ref.Doc. OSR RENT
 Doc. Currency USD
 Doc. Hdr Text OSR Rent

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1004140	ONE STAMFORD REALTY		GEN			602.027,08-	OSR Rent
2	40	130160	Deposits On Assets		GEN			602.027,08	

Document Overview - Display

Doc.Type : ZP (Payment posting) Normal document
 Doc. Number 2000150351 Company Code 208 Fiscal Year 2018
 Doc. Date 20.12.2018 Posting Date 20.12.2018 Period 12
 Calculate Tax ☐
 Doc. Currency USD
 Payment Run ID 20.12.2018 - PAY5

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1004140	ONE STAMFORD REALTY		GEN			602.027,08	
2	50	100010	Cash Concentration		GEN			602.027,08-	

Display Document: Line Item 001

Vendor 1004140 ONE STAMFORD REALTY LP G/L Acc 200010
 Company Code 208 201 TRESSER BLVD
 Purdue Pharma L.P. STAMFORD Doc. no. 2000150351
 Line Item 1 / Outgoing payment / 25
 Amount 602.027,08 USD

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

On January 1, 2008, Purdue entered into a security services agreement with PPTI, the service provider.

SECURITY SERVICES AGREEMENT

This Security Services Agreement (the "Agreement") effective as of January 1, 2008 by and between Purdue Pharma L.P., a Delaware limited partnership ("PPLP"), and Purdue Pharma Technologies Inc., a Delaware corporation ("PPTI"),

W I T N E S S E T H :

WHEREAS, PPTI is engaged in the security services business; and

WHEREAS, PPLP wishes to engage PPTI to perform security services in support of PPLP's business;

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter contained, the parties hereto agree as follows:

1. Direction of Services. At all times the services provided by PPTI to PPLP shall be subject to the direction and control of PPLP. PPTI shall consult with PPLP before incurring any expense or making any commitment for the benefit of PPLP that would give rise to an obligation on the part of PPLP to reimburse PPTI in the amount of \$1,000 or more or, in the case of a commitment involving periodic expenditures, in the aggregate amount of \$5,000 or more during any calendar year during the term of this Agreement.

2. Services to be Provided. During the term of this Agreement and subject to the provisions hereof, PPLP agrees to retain the services of PPTI to provide the following services:

(a) Security and security related services to be provided at such facilities as PPLP shall direct; and

(b) Such further services as may be agreed to from time to time, provided that such agreement is evidenced by a written amendment to this Agreement.

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

Pursuant to the security services agreement, Purdue agreed to pay costs and expenses incurred by PPTI plus a markup of 10%.

4. Invoices and Payment.

(a) Within thirty (30) days of the last day of each calendar quarter ending on the last day of each March, June, September and December (each a "Calendar Quarter"), PPTI shall submit to PPLP an invoice summarizing the costs and expenses incurred by PPTI in providing its services hereunder during such Calendar Quarter and containing a service charge in the amount of ten percent (10%) of such costs and expenses.

(b) Unless otherwise agreed, within thirty (30) days of receipt of PPTI's invoice pursuant to Section 4(a) above, PPLP shall pay the amount invoiced by PPTI for its services hereunder.

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

PPTI also provided Internal Audit and Environmental, Health & Safety (“EHS”) services to Purdue beginning in 2008; however, per discussions with Purdue and TXP there is no written agreement for these services.

Between January 1, 2008 and December 31, 2015, Purdue was charged \$100.1 million by PPTI for these various services (costs and expenses plus a 10% markup of \$9.1 million).¹ PPTI’s services were discontinued as of 2015.

Year	Security Charges	EHS Charges	Internal Audit Charges	Total Service Charges
2008	\$ 7,483,326	\$ 4,558,375	\$ 224,233	\$ 12,265,934
2009	7,466,631	5,416,074	492,527	13,375,232
2010	8,102,142	6,033,538	833,782	14,969,462
2011	8,165,239	6,746,851	730,625	15,642,715
2012	7,885,712	6,134,915	754,284	14,774,911
2013	6,933,088	3,569,348	969,354	11,471,790
2014	5,192,813	3,079,809	484,715	8,757,337
2015	5,387,673	2,941,390	551,484	8,880,547
Total	\$ 56,616,624	\$ 38,480,300	\$ 5,041,004	\$ 100,137,928

¹Amounts presented in this chart represent intercompany charges recognized in various expense accounts of PPLP (SAP company code 208) in SAP.

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

Amounts charged to Purdue by PPTI (SAP company code 409) for security, EHS, and internal audit expenses were credited to various expense accounts in SAP, including "mark up" accounts for service charges. Charges for 2008 are illustrated below.

CC Comparison w/o Commitments

Variation: Cost Center

Cost Center Group

- 2000409 Corp Interest 409
- 2100409 Executive Admin 409
- 2185409 Security - Corporate
- 2200409 General Counsel 409
- 2203409 Internal Audit
- 2301409 FINANCE 409
- 2370409 Fleet Info 409
- 2515409 Strmfd Bldg Serv 409
- 2530409 Security - Stamford
- 2531409 Security - Totowa
- 2532409 Security - Wilton
- 2533409 Security - Rhodes
- 2550409 EHS - Corporate
- 2570409 Emby Benefits 409
- 3100409 Totowa Wsh 409
- 330409 Western Wsh 409
- 440409 Security - Ewing 409
- 4404409 EHS - Ewing 409
- 6650409 EHS - Totowa
- 6651409 EHS - Wilton
- 6652409 EHS - Rhodes
- 900409 Dom Oth Inc_Exp 409
- 9001409 Foreign Inc_Exp 409
- CONT409 Contract OH 409

Cost Center Comparison Report with Company Code

Current Period: 12 2008

Plan Version: 0 Purdue Plan/Act - Version

Cost Center / Group: *

Company Code: 409 Purdue Pharma Technologies

Date: 06/25/2019

Time: 17:47:38

Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per. 1-12	Var %
608640 Outside Services	97,462	59,326	(38,136)	(64)	647,534	711,877	64,343	9
608650 Calibration Services	0	50	50	100	3,532	600	(2,932)	(489)
608660 Consultants - Mgmt.	26,450	58,517	32,067	55	419,524	702,200	282,676	40
608680 Consultants- IT (com)	0	0	0	0	1,190	0	(1,190)	0
608690 Consulting-Safety	14,661	7,642	(7,019)	(92)	81,660	91,700	10,040	11
609350 Seminars & Symposia	0	250	250	100	0	3,000	3,000	100
609480 Laboratory Supplies	1,176	0	(1,176)	0	2,846	0	(2,846)	0
609550 Safety Supplies	10,373	12,123	1,750	14	219,049	145,480	(73,569)	(51)
609570 Security Supplies	(87)	3,458	3,546	103	26,281	41,500	15,219	37
611615 Community Rel Supp.	0	83	83	100	0	1,000	1,000	100
611625 Law Enforce Affairs	1,767	44,167	42,399	96	472,452	530,000	57,548	11
640000 Contributions	0	0	0	0	(80)	0	80	0
650020 Permits	120	3,619	3,499	97	20,790	45,825	25,035	55
650030 Sales Tax Expense	(17,023)	1,109	15,132	1,435	95,924	13,308	(82,616)	(621)
660030 Interest Other	0	0	0	0	0	0	0	0
660040 Interest Interco	21,942	41,167	19,224	47	445,248	494,000	48,752	10
690100 InterCo Charge/Credit	(602,585)	(21,003)	581,582	(2,769)	(808,964)	(252,086)	556,878	(221)
700015 Int. Income Tax Pay	0	0	0	0	0	0	0	0
700130 Partnership Income	6,415	0	(6,415)	0	6,415	0	(6,415)	0
700199 Functional Area Revo	(44)	0	44	0	(44)	0	44	0
700510 Unrealized FX	(154,025)	0	154,025	0	(144,998)	0	144,998	0
790100 PM Internal Std Rate	0	0	0	0	44	0	(44)	0
793030 Security Assessm	(483,064)	(584,993)	(101,929)	17	(6,453,324)	(7,227,988)	(426,964)	6
793130 Security mark up	(48,306)	(56,499)	(10,193)	17	(660,302)	(722,799)	(42,497)	6
793140 EHS Cost Assessm	(392,389)	(406,233)	(13,844)	3	(4,143,977)	(4,967,845)	(823,867)	17
793150 EHS Cost mark up	(39,239)	(40,623)	(1,384)	3	(424,398)	(496,785)	(82,387)	17
793160 T&P Cost Assessm	1,965	0	(1,965)	0	15,874	0	(15,874)	0
793170 T&P MARK UP	197	0	(197)	0	1,587	0	(1,587)	0
800000 Misc. Charge/Expense	0	0	0	0	0	0	0	0
* Total	(264,652)	(26,350)	238,303	(904)	(843,736)	(323,479)	520,257	(161)

CC Comparison w/o Commitments

Variation: Cost Center

Cost Center Group

- 2000409 Corp Interest 409
- 2100409 Executive Admin 409
- 2185409 Security - Corporate
- 2200409 General Counsel 409
- 2203409 Internal Audit
- 2301409 FINANCE 409
- 2370409 Fleet Info 409
- 2515409 Strmfd Bldg Serv 409
- 2530409 Security - Stamford
- 2531409 Security - Totowa
- 2532409 Security - Wilton
- 2533409 Security - Rhodes
- 2550409 EHS - Corporate
- 2570409 Emby Benefits 409
- 3100409 Totowa Wsh 409
- 330409 Western Wsh 409
- 440409 Security - Ewing 409
- 4404409 EHS - Ewing 409
- 6650409 EHS - Totowa
- 6651409 EHS - Wilton
- 6652409 EHS - Rhodes

Cost Center Comparison Report with Company Code

Current Period: 12 2008

Plan Version: 0 Purdue Plan/Act - Version

Cost Center / Group: 2203409 Internal Audit

Company Code: 409 Purdue Pharma Technologies

Date: 06/25/2019

Time: 17:48:32

Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per. 1-12	Var %
603000 Salaries - Exempt	13,212	11,694	(1,518)	(13)	156,667	152,022	(4,645)	(3)
604000 Payroll Taxes	270	178	(92)	(52)	9,301	9,116	(185)	(2)
606000 Annual Bonus	32,130	0	(32,130)	0	32,130	0	(32,130)	0
606300 Admin and Prof Trav.	1,122	837	(285)	(34)	3,041	10,004	6,962	70
606420 Meals and Ent.	163	163	0	0	353	1,996	1,643	82
606810 Ext. Training Exp.	0	250	250	100	474	3,000	2,526	84
606850 Office Supplies	0	38	38	100	0	496	496	100
607300 Dues	0	57	57	100	480	974	524	54
607310 Subscript. - Books	0	57	57	100	830	974	144	15
607320 Subscript. - Journals	0	0	0	0	338	0	(338)	0
608640 Outside Services	0	837	837	100	0	10,004	10,004	100
690100 InterCo Charge/Credit	(17,854)	(21,003)	(3,149)	15	(224,233)	(252,086)	(27,854)	11
792000 Fringe Benefits	2,759	2,754	(5)	(0)	33,102	33,048	(54)	(0)
792010 Fleet Allocation	0	876	876	100	0	7,488	7,488	100
* Total	31,797	(3,562)	(35,359)	993	12,653	(22,965)	(35,618)	155

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

Amounts charged for internal audit, security, and EHS were not settled in cash on a regular basis between PPTI and PPLP; rather, PPLP would fund the balance in account 102409 (Intercompany Account – PPTI) on an ad hoc basis.

PPLP's intercompany activity with PPTI for 2015 is illustrated below.

G/L Account Balance Display

Document currency

Document currency

Document currency

Business area

Business area

Account number

102409

Purdue Pharma Tech

Company code

208

Purdue Pharma L.P.

Business area

Fiscal year

2015

All documents in currency

*

Display currency

USD

Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				7.940.254,92-
1	1.587.294,41	566.842,57	1.020.451,84	6.919.803,08-
2	2.153.747,43	470.692,72	1.683.054,71	5.236.748,37-
3	2.175.660,93	9.606.485,63	7.430.824,70-	12.667.573,07-
4	3.419.717,30	8.528.816,95	5.109.099,65-	17.776.672,72-
5	2.162.547,43	498.551,82	1.663.995,61	16.112.677,11-
6	2.138.447,85	4.945.060,11	2.806.612,26-	18.919.289,37-
7	2.209.580,67	648.234,07	1.561.346,60	17.357.942,77-
8	2.215.912,75	468.242,80	1.747.669,95	15.610.272,82-
9	2.499.465,87	831.689,94	1.667.775,93	13.942.496,89-
10	1.668.314,39	576.834,14	1.091.480,25	12.851.016,64-
11	2.258.535,18	593.529,67	1.665.005,51	11.186.011,13-
12	4.441.499,26	11.184.014,11	6.742.514,85-	17.928.525,98-
13				17.928.525,98-
14				17.928.525,98-
15				17.928.525,98-
16				17.928.525,98-
Total	28.930.723,47	38.918.994,53	9.988.271,06-	17.928.525,98-

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

From 2012 to 2017, at Ernst & Young's ("E&Y") request, Purdue prepared an intercompany analysis of account 102409 (SAP company code 208). The 2015 PPTI intercompany analysis is illustrated below with relevant cells highlighted, including the ad hoc cash payments used to fund intercompany activities.¹ The beginning and ending balances reconcile to the SAP balances on the previous slide.

PP Tech Intercompany Analysis As of December 31, 2015

Description	109	208	213	219	240	241	307	313	318	Total
Beginning Balance	-	(7,940,255)	-	-	-	-	-	-	-	(7,940,255)
Fundings	-	16,550,000	-	-	-	-	-	-	-	16,550,000
Reconciliation Posting CO (Note 1)	(465,125)	(6,000,769)	-	(1,707,224)	-	-	-	-	(155,946)	(8,329,063)
Inventory Sweep Entry (Note 3)	-	-	-	-	-	(6,119,334)	(10,430,484)	(3,761,270)	-	(20,311,089)
Third Party Manufacturing (Note 4)	-	-	-	-	-	(380,689)	(342,076)	(791,373)	-	(1,514,139)
Purchase Price Variance (Note 5)	-	-	-	-	-	(12,172)	1,857,664	761	-	1,846,253
Contract Overhead	-	-	-	-	-	-	505,645	829,218	-	1,334,863
Commission	-	-	-	-	-	(811,985)	(203,568)	-	-	(1,015,553)
Benefits (Note 2)	4,458	1,165,273	-	7,895	-	-	-	-	-	1,177,626
Fleet Costs	-	101,724	-	-	-	-	-	-	-	101,724
Internal Audit Charge including markup	-	(564,906)	-	-	-	-	-	-	-	(564,906)
ExpenSite	-	194,221	-	-	-	-	-	-	-	194,221
Comdata Payments	-	738,684	-	-	-	-	-	-	-	738,684
Intercompany Interest	(776)	(134,445)	-	(3,539)	-	(14,060)	(15,248)	(8,294)	(279)	(176,640)
Other	(6,791)	(20,177)	-	(31,611)	-	-	189	12,115	26,023	(20,251)
LCD Entry	468,234	(22,017,876)	-	1,734,478	-	7,338,241	8,627,879	3,718,843	130,201	0
Ending Balance	-	(17,928,526)	-	-	-	-	-	-	-	(17,928,526)

Note 1 - represents the cost plus 10% markup of EHS and security services provided by PP tech to various entities. See Attachment 1.

Note 2 - represents charges for CIGNA, Anthem, Medco, United Healthcare, 401k, etc. charges that are provided to employees of PP Tech and paid for by PPLP.

Note 3 - represents amounts due to PP Tech relating to inventory that is procured by PP Tech and then sold to companies 241, 307 and 313 "distribution companies" which are the companies which sell Purdue products. See Attachment 2.

Note 4 - represents 3rd party manufacturing related work commissioned by PP Tech on behalf of the distribution companies, including brokerage commission and commission expense.

Note 5 - PPV relates to inventoried materials (raw, packaging, finished). PPV is the difference between our standard cost (USC) vs. the actual cost. Because the relationship between Purdue and contract manufacturers is conducted under company 409 all costs are moved out of company 409 to the distributing company at month end and assessed a 5% brokerage commission.

¹ The Purdue entities receiving internal audit, security, and EHS services from PPTI are The P.F. Laboratories Inc. (SAP company code 109), Purdue Pharma L.P. (SAP company code 208), Purdue Pharmaceuticals L.P. (SAP company code 219), and Purdue Pharma Manufacturing L.P. (SAP company code 218).

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

The ad hoc cash payments made by PPLP used to fund intercompany activities with PPTI in 2015 are illustrated below. These amounts reconcile to the ad hoc cash payments labeled “fundings” from the previous slide.

G/L Account Line Item Display

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

The last ad hoc cash payment made by PPLP used to fund intercompany activities with PPTI in 2015 is illustrated below. This amount reconciles to the previous slide.

Document Overview - Display

Doc.Type : SA (G/L account document) Normal document

Doc. Number	100154298	Company Code	208	Fiscal Year	2015
Doc. Date	04.01.2016	Posting Date	20.12.2015	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100010665409 15		
Doc. Currency	USD				
Doc. Hdr Text	CTW409 12142015-12202015				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			2.000.000,00-	CORP PAY
2	40	102409	Purdue Pharma Tech		GEN			2.000.000,00	

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

The table below illustrates that for the years 2012 through 2017 (the years for which the intercompany reconciliation analysis was performed for E&Y):

- 1) Income statement charges roughly approximate balance sheet charges with annual variances due to timing differences; and
- 2) The difference between the balance sheet charges (\$161 million) and the ad hoc funding (\$156 million) is only \$5 million at the end of 2017, indicating that Purdue was making regular cash payments to satisfy the intercompany charges.¹

Description	2012	2013	2014	2015	2016	2017	Cumulative Total: 2012 - 2017
3rd Party Purchasing:							
Balance Sheet Charges	\$ 32,522,583	\$ 22,972,784	\$ 22,926,201	\$ 19,659,665	\$ 20,310,947	\$ 12,234,581	\$ 130,626,761
Income Statement Charges	32,866,635	26,307,510	24,181,836	20,311,089	21,279,185	13,055,169	138,001,424
Difference	(344,052)	(3,334,726)	(1,255,635)	(651,424)	(968,238)	(820,588)	(7,374,663)
Internal Audit, EHS, Security Services							
Balance Sheet Charges	10,909,423	11,395,545	8,646,898	8,893,969	(3,182)	-	39,842,653
Income Statement Charges	14,774,911	11,471,790	8,757,337	8,880,547	-	-	43,884,585
Difference	(3,865,488)	(76,245)	(110,439)	13,422	(3,182)	-	(4,041,932)
Other Balance Sheet Charges							
Other Balance Sheet Charges	(1,770,897)	(776,646)	(1,902,020)	(2,015,363)	(1,360,287)	(1,222,803)	(9,048,016)
Total Balance Sheet Charges	\$ 41,661,109	\$ 33,591,682	\$ 29,671,079	\$ 26,538,271	\$ 18,947,479	\$ 11,011,778	\$ 161,421,398
Funding - PPLP to PPTI	39,100,000	37,326,944	30,145,000	16,550,000	20,000,000	13,000,000	156,121,944
Difference - Funding vs. Balance Sheet Charges	\$ 2,561,109	\$ (3,735,262)	\$ (473,921)	\$ 9,988,271	\$ (1,052,521)	\$ (1,988,222)	\$ 5,299,454

¹PPLP charges PPTI for various costs related to labor, benefits, travel & entertainment, fleet, intercompany interest, etc. Charges for these other items represent the remaining portion of the activity in account 102409 for SAP company code 208. PPTI similarly charges PPLP for 3rd party purchasing services. Per discussions with Purdue and TXP, no formal agreements exist for these arrangements. For more information on 3rd party purchasing services and other service charges, please see Exhibits 1D and 1P.

Exhibit 1C: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for internal audit, security, and environmental, health & safety services

Intercompany analyses of account 102409 (Intercompany account – PPTI) in PPLP’s accounting records (SAP company code 208) were only created for years 2012 to 2017. Based on discussions with Purdue and TXP, creating similar analyses for other years would be burdensome and very time consuming.

Alternatively, a comparison of all debits versus credits in the intercompany account between PPLP and PPTI since 2008, in conjunction with the conclusions from the previous slide, indicates that all intercompany activity was ultimately settled in cash since the ending balance as of September 15, 2019 is \$42,482.

Account 102409 Company 208	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Prior Year Cumulative Balance	\$ (211,005)	\$ (2,210,437)	\$ (3,541,336)	\$ (6,587,449)	\$ (983,661)	\$ (11,983,484)	\$ (8,414,176)	\$ (7,940,255)	\$ (17,928,526)	\$ (16,876,005)	\$ (15,067,328)	\$ 614,270
Debits	24,682,596	24,998,987	29,644,606	43,398,128	42,996,919	48,200,557	36,984,290	28,930,723	23,007,403	15,801,645	16,054,326	288,643
Credits	(26,682,027)	(26,329,886)	(32,690,719)	(37,794,340)	(53,996,742)	(44,631,249)	(36,510,369)	(38,918,995)	(21,954,881)	(13,992,968)	(372,728)	(860,431)
Ending Cumulative Balance	\$ (2,210,437)	\$ (3,541,336)	\$ (6,587,449)	\$ (983,661)	\$ (11,983,484)	\$ (8,414,176)	\$ (7,940,255)	\$ (17,928,526)	\$ (16,876,005)	\$ (15,067,328)	\$ 614,270	\$ 42,482

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

On January 1, 2008, Purdue entered into a purchasing services agreement with PPTI, the service provider.

PURCHASING SERVICES AGREEMENT

This Purchasing Services Agreement (the "Agreement") effective as of January 1, 2008 by and between Purdue Products L.P., a Delaware limited partnership ("PPLP"), and Purdue Pharma Technologies Inc., a Delaware corporation ("PPTI"),

W I T N E S S E T H :

WHEREAS, PPTI is engaged in the purchasing services business; and

WHEREAS, PPLP wishes to engage PPTI to perform purchasing services in support of PPLP's business;

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter contained, the parties hereto agree as follows:

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

Pursuant to this purchasing servicing agreement, Purdue agreed to pay costs and expenses incurred by PPTI plus a service charge of [REDACTED].

4. Invoices and Payment.

(a) Within thirty (30) days of the last day of each calendar quarter ending on the last day of each March, June, September and December (each a "Calendar Quarter"), PPTI shall submit to PPLP an invoice summarizing the costs and expenses incurred by PPTI in providing its services hereunder during such Calendar Quarter and containing a service charge in the amount of [REDACTED] of such costs and expenses.

(b) Unless otherwise agreed, within thirty (30) days of receipt of PPTI's invoice pursuant to Section 4(a) above, PPLP shall pay the amount invoiced by PPTI for its services hereunder.

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

Since January 1, 2008, Purdue was charged \$182.1 million by PPTI (costs plus a [REDACTED] markup of [REDACTED]) pursuant to the purchasing services agreement. Per discussions with Purdue and TXP, purchasing services ended in 2017.

Year	Charges for
	Purchasing Services
2008	\$ 5,760,344
2009	11,802,711
2010	11,092,517
2011	15,467,233
2012	32,866,635
2013	26,307,510
2014	24,181,836
2015	20,311,089
2016	21,279,185
2017	13,055,169
Total	\$ 182,124,228

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

Amounts for purchasing services charged to Purdue by PPTI (SAP company code 409) to G/L account 404010 (Sales – External Finished Goods) represent “sweep” entries processed by SAP (2008 and 2017 shown below). These sweep entries automatically recognize sales and cost of goods sold related to 3rd party purchases and allocate them to specific companies, including PPTI.

G/L Account Line Item Display														
<div><div><div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div></div></div>														

G/L Account Line Item Display														
G/L Account 404010 Sales Finished Goods External Company Code 409														
CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 01 2017	354,997.47-	USD	
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 01 2017	288,161.65-	USD	
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	CLC	External COGS (stk Trf) Mfg Sweep Entry 01 2017	214,455.46-	USD	
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	PCL	External COGS (stk Trf) Mfg Sweep Entry 01 2017	210,742.97-	USD	
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 01 2017	150,740.72-	USD	
409	100011103	31.01.2017	01.02.2017	1	2017/01	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 01 2017	878,323.97-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 02 2017	100,834.97-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 02 2017	305,870.86-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	CLC	External COGS (stk Trf) Mfg Sweep Entry 02 2017	1,055,216.20-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	PCL	External COGS (stk Trf) Mfg Sweep Entry 02 2017	128,147.27-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 02 2017	90,677.95-	USD	
409	100011120	29.02.2017	01.03.2017	2	2017/02	ZG		XXX	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 02 2017	700,147.19-	USD	
409	100011158	31.03.2017	03.04.2017	3	2017/03	SA		LMT 0317	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 03 2017	381,184.09-	USD	
409	100011158	31.03.2017	03.04.2017	3	2017/03	SA		LMT 0317	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 03 2017	161,274.45-	USD	
409	100011155	31.03.2017	03.04.2017	3	2017/03	SA		LMT 0317	404010	CLC	External COGS (stk Trf) Mfg Sweep Entry 03 2017	482,590.91-	USD	
409	100011155	31.03.2017	03.04.2017	3	2017/03	SA		LMT 0317	404010	PCL	External COGS (stk Trf) Mfg Sweep Entry 03 2017	128,127.64-	USD	
409	100011155	31.03.2017	03.04.2017	3	2017/03	SA		LMT 0317	404010	SEN	External COGS (stk Trf) Mfg Sweep Entry 03 2017	132,341.04-	USD	
409	100011174	30.04.2017	01.05.2017	4	2017/04	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 04 2017	95,377.65-	USD	
409	100011174	30.04.2017	01.05.2017	4	2017/04	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 04 2017	32,033.68-	USD	
409	100011174	30.04.2017	01.05.2017	4	2017/04	ZG			404010	CLC	F output to Mfg Mfg Sweep Entry 04 2017	675,043.38-	USD	
409	100011174	30.04.2017	01.05.2017	4	2017/04	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 04 2017	228,549.68-	USD	
409	100011174	30.04.2017	01.05.2017	4	2017/04	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 04 2017	965,734.09-	USD	
409	100011120	31.05.2017	01.06.2017	5	2017/05	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 05 2017	101,787.25-	USD	
409	100011120	31.05.2017	01.06.2017	5	2017/05	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 05 2017	100,944.00-	USD	
409	100011180	31.05.2017	01.06.2017	5	2017/05	ZG			404010	CLC	F output to Mfg Mfg Sweep Entry 05 2017	276,223.11-	USD	
409	100011180	31.05.2017	01.06.2017	5	2017/05	ZG			404010	PCL	F output to Mfg Mfg Sweep Entry 05 2017	113,011.95-	USD	
409	100011180	31.05.2017	01.06.2017	5	2017/05	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 05 2017	225,494.55-	USD	
409	100011101	31.05.2017	01.06.2017	5	2017/05	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 05 2017	1,102,790.66-	USD	
409	100011210	30.06.2017	05.07.2017	6	2017/06	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 06 2017	177,389.54-	USD	
409	100011210	30.06.2017	05.07.2017	6	2017/06	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 06 2017	214,300.43-	USD	
409	100011210	30.06.2017	05.07.2017	6	2017/06	ZG			404010	CLC	F output to Mfg Mfg Sweep Entry 06 2017	193,398.23-	USD	
409	100011210	30.06.2017	05.07.2017	6	2017/06	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 06 2017	447,741.38-	USD	
409	100011232	31.07.2017	01.08.2017	7	2017/07	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 07 2017	13,770.57-	USD	
409	100012320	31.07.2017	01.08.2017	7	2017/07	ZG			404010	CLC	F output to Mfg Mfg Sweep Entry 07 2017	459,904.40-	USD	
409	100012322	31.07.2017	01.08.2017	7	2017/07	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 07 2017	699,101.25-	USD	
409	100011249	31.08.2017	01.09.2017	8	2017/08	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 08 2017	123,064.24-	USD	
409	100011300	30.11.2017	01.12.2017	11	2017/11	ZG			404010	SEN	F output to Mfg Mfg Sweep Entry 11 2017	24,599.04-	USD	
409	100011315	31.12.2017	02.01.2018	12	2017/12	ZG			404010	CLC	F output to Mfg Mfg Sweep Entry 12 2017	190,950.05-	USD	
												13,055,169.95-	USD	

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

Per discussions with Purdue and TXP, amounts charged for purchasing services were not settled on a regular basis between PPTI and PPLP; rather, PPLP would fund the balance in account 102409 (Intercompany Account – PPTI) on an ad hoc basis.

The 2015 PPTI intercompany analysis is illustrated below with relevant cells highlighted, including the ad hoc cash payments used to fund intercompany activities. The beginning and ending balances reconcile to the intercompany SAP balances on slide 88.

PP Tech Intercompany Analysis As of December 31, 2015

Description	109	208	213	219	240	241	307	313	318	Total
Beginning Balance	-	(7,940,255)	-	-	-	-	-	-	-	(7,940,255)
Fundings	-	16,550,000	-	-	-	-	-	-	-	16,550,000
Reconciliation Posting CO (Note 1)	(465,125)	(6,000,769)	-	(1,707,224)	-	-	-	-	(155,946)	(8,329,063)
Inventory Sweep Entry (Note 3)	-	-	-	-	-	(6,119,334)	(10,430,484)	(3,761,270)	-	(20,311,089)
Third Party Manufacturing (Note 4)	-	-	-	-	-	(380,689)	(342,076)	(791,373)	-	(1,514,139)
Purchase Price Variance (Note 5)	-	-	-	-	-	(12,172)	1,857,664	761	-	1,846,253
Contract Overhead	-	-	-	-	-	-	505,645	829,218	-	1,334,863
Commission	-	-	-	-	-	(811,985)	(203,568)	-	-	(1,015,553)
Benefits (Note 2)	4,458	1,165,273	-	7,895	-	-	-	-	-	1,177,626
Fleet Costs	-	101,724	-	-	-	-	-	-	-	101,724
Internal Audit Charge including markup	-	(564,906)	-	-	-	-	-	-	-	(564,906)
ExpenSite	-	194,221	-	-	-	-	-	-	-	194,221
Comdata Payments	-	738,684	-	-	-	-	-	-	-	738,684
Intercompany Interest	(776)	(134,445)	-	(3,539)	-	(14,060)	(15,248)	(8,294)	(279)	(176,640)
Other	(6,791)	(20,177)	-	(31,611)	-	-	189	12,115	26,023	(20,251)
LCD Entry	468,234	(22,017,876)	-	1,734,478	-	7,338,241	8,627,879	3,718,843	130,201	0
Ending Balance	-	(17,928,526)	-	-	-	-	-	-	-	(17,928,526)

Note 1 - represents the cost plus 10% markup of EHS and security services provided by PP tech to various entities. See Attachment 1.

Note 2 - represents charges for CIGNA, Anthem, Medco, United Healthcare, 401k, etc. charges that are provided to employees of PP Tech and paid for by PPLP.

Note 3 - represents amounts due to PP Tech relating to inventory that is procured by PP Tech and then sold to companies 241, 307 and 313 "distribution companies" which are the companies which sell Purdue products. See Attachment 2.

Note 4 - represents 3rd party manufacturing related work commissioned by PP Tech on behalf of the distribution companies, including brokerage commission and commission expense.

Note 5 - PPV relates to inventoried materials (raw, packaging, finished). PPV is the difference between our standard cost (USC) vs. the actual cost. Because the relationship between Purdue and contract manufacturers is conducted under company 409 all costs are moved out of company 409 to the distributing company at month end and assessed a 5% brokerage commission.

¹ The Purdue entities receiving finished products from PPTI are Purdue Transdermal Technologies L.P. (SAP company code 241), Purdue Products L.P. (SAP company code 307; now known as Avrio Health L.P.), and Purdue Pharmaceutical Products L.P. (SAP company code 313).

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

The table below illustrates that for the years 2012 through 2017 (the years for which the intercompany reconciliation analysis was performed for E&Y):

- 1) Income statement charges roughly approximate balance sheet charges with annual variances due to timing differences; and
- 2) The difference between the balance sheet charges (\$156 million) and the ad hoc funding (\$161 million) is only \$5 million at the end of 2017, indicating that Purdue was making regular cash payments to satisfy the intercompany charges.

Description	2012	2013	2014	2015	2016	2017	Cumulative Total: 2012 - 2017
3rd Party Purchasing:							
Balance Sheet Charges	\$ 32,522,583	\$ 22,972,784	\$ 22,926,201	\$ 19,659,665	\$ 20,310,947	\$ 12,234,581	\$ 130,626,761
Income Statement Charges	32,866,635	26,307,510	24,181,836	20,311,089	21,279,185	13,055,169	138,001,424
Difference	(344,052)	(3,334,726)	(1,255,635)	(651,424)	(968,238)	(820,588)	(7,374,663)
Internal Audit, EHS, Security Services							
Balance Sheet Charges	10,909,423	11,395,545	8,646,898	8,893,969	(3,182)	-	39,842,653
Income Statement Charges	14,774,911	11,471,790	8,757,337	8,880,547	-	-	43,884,585
Difference	(3,865,488)	(76,245)	(110,439)	13,422	(3,182)	-	(4,041,932)
Other Balance Sheet Charges	(1,770,897)	(776,646)	(1,902,020)	(2,015,363)	(1,360,287)	(1,222,803)	(9,048,016)
Total Balance Sheet Charges	\$ 41,661,109	\$ 33,591,682	\$ 29,671,079	\$ 26,538,271	\$ 18,947,479	\$ 11,011,778	\$ 161,421,398
Funding - PPLP to PPTI	39,100,000	37,326,944	30,145,000	16,550,000	20,000,000	13,000,000	156,121,944
Difference - Funding vs. Balance Sheet Charges	\$ 2,561,109	\$ (3,735,262)	\$ (473,921)	\$ 9,988,271	\$ (1,052,521)	\$ (1,988,222)	\$ 5,299,454

¹PPLP, in the ordinary course of business, charges PPTI for various costs related to labor, benefits, travel & entertainment, fleet, intercompany interest, etc. Charges for these other items represent the remaining portion of the activity in account 102409 for SAP company code 208. Per discussions with Purdue and TXP, no formal agreements exist for these arrangements. PPTI similarly charges PPLP for internal audit, security, and EHS. For more information on internal audit, security, and EHS and other service charges, please see Exhibits 1C and 1P.

Exhibit 1D: Intercompany transfers between Purdue and Purdue Pharma Technologies Inc. for finished products from 3rd parties

Intercompany analyses of account 102409 (Intercompany account – PPTI) in PPLP’s accounting records (SAP company code 208) were only created for years 2012 to 2017. Based on discussions with Purdue and TXP, creating similar analyses for other years would be burdensome and very time consuming.

Alternatively, a comparison of all debits versus credits in the intercompany account between PPLP and PPTI since 2008, in conjunction with the conclusions from the previous slide, indicates that all intercompany activity was ultimately settled in cash since the ending balance as of September 15, 2019 is \$42,482.

Account 102409 Company 208	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Prior Year Cumulative Balance	\$ (211,005)	\$ (2,210,437)	\$ (3,541,336)	\$ (6,587,449)	\$ (983,661)	\$ (11,983,484)	\$ (8,414,176)	\$ (7,940,255)	\$ (17,928,526)	\$ (16,876,005)	\$ (15,067,328)	\$ 614,270
Debits	24,682,596	24,998,987	29,644,606	43,398,128	42,996,919	48,200,557	36,984,290	28,930,723	23,007,403	15,801,645	16,054,326	288,643
Credits	(26,682,027)	(26,329,886)	(32,690,719)	(37,794,340)	(53,996,742)	(44,631,249)	(36,510,369)	(38,918,995)	(21,954,881)	(13,992,968)	(372,728)	(860,431)
Ending Cumulative Balance	\$ (2,210,437)	\$ (3,541,336)	\$ (6,587,449)	\$ (983,661)	\$ (11,983,484)	\$ (8,414,176)	\$ (7,940,255)	\$ (17,928,526)	\$ (16,876,005)	\$ (15,067,328)	\$ 614,270	\$ 42,482

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

On January 1, 1996, Purdue entered into a contract manufacturing agreement with The P.F. Laboratories Inc. ("P.F. Labs."), the manufacturer, to manufacture MS Contin as listed in Exhibit A to the agreement.

CONTRACT MANUFACTURING AGREEMENT

Contract Manufacturing Agreement dated as of
January 1, 1996 by and between THE P.F. LABORATORIES, INC.,
a New Jersey corporation ("Manufacturer"), and PURDUE PHARMA
L.P., a Delaware limited partnership ("Purchaser"),

W I T N E S S E T H :

WHEREAS, Purchaser has the rights to produce and
sell certain pharmaceutical products and preparations listed
on Exhibit A hereto, as the same may be amended from time to
time (collectively, the "Preparations"); and

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

Pursuant to the manufacturing agreement, Purdue agreed to pay P.F. Labs: i) material costs, ii) all other costs (hereinafter "manufacturing costs" for items i) and ii), and iii) 10% of said costs as a sales commission.

5. Price.

(a) During the term of this Agreement, Manufacturer's base price per unit of each Preparation (the "Base Price") to Purchaser shall consist of

(i) Manufacturer's estimated direct costs for raw materials and packaging materials calculated on a standard cost system basis ("Material Costs"), plus (ii) all other estimated direct and indirect costs, including shipping and overhead costs, estimated to be incurred by Manufacturer with respect to the Manufacture of each Preparation ("Other Costs"), plus (iii) an amount equal to 10% of the sum of clauses (i) and (ii) of this Section 5(a).

6. Invoicing and Payment. Manufacturer shall periodically, but not more frequently than monthly, submit to Purchaser an invoice for the Preparations Manufactured by Manufacturer for Purchaser, and each invoice shall be prepared in accordance with the procedures set forth in Section 5 above. Purchaser shall pay, against Manufacturer's invoice therefor, the invoiced amount for such Preparation in accordance with Manufacturer's normal terms.


Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

From 2008 to 2014, Purdue was charged \$17 million for manufacturing costs and \$1.7 million in markups, totaling \$18.7 million. Per discussions with Purdue, manufacturing ceased in 2014 because the manufacturing facility was sold in 2015.

Year	Manufacturing Costs	Service Commissions	Total	Markups as % of Manufacturing Costs
2008	\$ 10,021,395	\$ 1,002,139	\$ 11,023,534	10%
2009	4,221,947	422,197	4,644,144	10%
2010	1,222,995	122,300	1,345,295	10%
2011	666,280	66,628	732,908	10%
2012	381,294	38,129	419,424	10%
2013	217,444	21,744	239,188	10%
2014	277,690	27,769	305,459	10%
Total	\$ 17,009,044	\$ 1,700,907	\$ 18,709,951	10%

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

According to P.F. Labs's accounting records in SAP, P.F. Labs (SAP company code 109) incurred \$17 million in manufacturing costs from 2008 to 2014 related to Purdue through G/L account 404000 (Gross Sales – Manufacturing).

G/L Account Company Code		404000 109	Gross Sales - Manufacturing								
DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Account	Profit Ctr	Text	Amount in local cur.	LCur	
<input type="checkbox"/> 100006879	31.01.2009	09.02.2009	1	2009/01	ZG	404000	UNI	F output to Mfg Mfg Sweep Entry 01 2009	103.405,10-	USD	
<input type="checkbox"/> 100007060	28.02.2009	02.03.2009	2	2009/02	ZG	404000	MSG	F output to Mfg Mfg Sweep Entry 02 2009	1.057.103,88-	USD	
<input type="checkbox"/> 100007269	31.03.2009	02.04.2009	3	2009/03	ZG	404000	MSG	F output to Mfg Mfg Sweep Entry 03 2009	923.564,00-	USD	
<input type="checkbox"/> 100007269	31.03.2009	02.04.2009	3	2009/03	ZG	404000	OXI	F output to Mfg Mfg Sweep Entry 03 2009	162.909,98-	USD	
<input type="checkbox"/> 100007494	30.04.2009	30.04.2009	4	2009/04	ZG	404000	MSG	F output to Mfg Mfg Sweep Entry 04 2009	512.778,30-	USD	
<input type="checkbox"/> 100007494	30.04.2009	30.04.2009	4	2009/04	ZG	404000	OXI	F output to Mfg Mfg Sweep Entry 04 2009	220.075,77-	USD	
<input type="checkbox"/> 100007704	31.05.2009	31.05.2009	5	2009/05	ZG	404000	OXI	F output to Mfg Mfg Sweep Entry 05 2009	111.904,71-	USD	
<input type="checkbox"/> 100007704	31.05.2009	31.05.2009	5	2009/05	ZG	404000	OXY	F output to Mfg Mfg Sweep Entry 05 2009	320.514,56-	USD	
<input type="checkbox"/> 100007704	31.05.2009	31.05.2009	5	2009/05	ZG	404000	UNI	F output to Mfg Mfg Sweep Entry 05 2009	114.458,18-	USD	
<input type="checkbox"/> 100007876	30.06.2009	30.06.2009	6	2009/06	ZG	404000	OXI	F output to Mfg Mfg Sweep Entry 06 2009	55.596,49-	USD	
<input type="checkbox"/> 100007876	30.06.2009	30.06.2009	6	2009/06	ZG	404000	UNI	F output to Mfg Mfg Sweep Entry 06 2009	205.911,02-	USD	
<input type="checkbox"/> 100008122	31.08.2009	31.08.2009	8	2009/08	ZG	404000	OXY	F output to Mfg Mfg Sweep Entry 08 2009	169.679,80-	USD	
<input type="checkbox"/> 100009890	30.09.2010	30.09.2010	9	2010/09	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 09 2010	286.090,87-	USD	
<input type="checkbox"/> 100010042	31.10.2010	31.10.2010	10	2010/10	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 10 2010	936.904,35-	USD	
<input type="checkbox"/> 100011116	31.05.2011	31.05.2011	5	2011/05	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 05 2011	324.261,48-	USD	
<input type="checkbox"/> 100011912	31.12.2011	31.12.2011	12	2011/12	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 12 2011	342.018,67-	USD	
<input type="checkbox"/> 100012608	30.06.2012	30.06.2012	6	2012/06	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 06 2012	237.916,54-	USD	
<input type="checkbox"/> 100013027	31.10.2012	31.10.2012	10	2012/10	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 10 2012	143.377,60-	USD	
<input type="checkbox"/> 100013748	31.05.2013	31.05.2013	5	2013/05	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 05 2013	217.443,77-	USD	
<input type="checkbox"/> 100015097	30.09.2014	02.10.2014	9	2014/09	ZG	404000	ORF	F output to Mfg Mfg Sweep Entry 09 2014	277.689,56-	USD	
									17.009.044,10-	USD	

Note:

- The SAP screenshot does not include all entries – excerpt version shown.

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

According to P.F. Labs's accounting records in SAP, P.F. Labs (SAP company code 109) earned \$1.7 million in 10% markup from 2008 to 2014 related to Purdue through G/L account 404030 (Sales Commission).

G/L Account Company Code		404030 109	Sales Commission							
DocumentNo	Pstng Date	Doc. Date	Year/month	Type	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 100007266	31.03.2009	31.03.2009	2009/03	SA	TS0309_TOT COMM	404030	OXI		16.291,00-	USD
<input type="checkbox"/> 100007486	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83-	USD
<input type="checkbox"/> 100007487	30.04.2009	30.04.2009	2009/04	AB	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83	USD
<input type="checkbox"/> 100007488	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83-	USD
<input type="checkbox"/> 100007488	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	OXI	Totowa Commission	22.007,58-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	UNI		11.445,82-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	OXI		11.190,47-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	OXY		32.054,13-	USD
<input type="checkbox"/> 100007872	30.06.2009	30.06.2009	2009/06	SA	TS0609_TOTOCOMM	404030	OXI	Commission	5.559,65-	USD
<input type="checkbox"/> 100007872	30.06.2009	30.06.2009	2009/06	SA	TS0609_TOTOCOMM	404030	UNI	Commission	20.591,10-	USD
<input type="checkbox"/> 100008112	31.08.2009	31.08.2009	2009/08	SA	TS0809_TOTCOMM	404030	OXY		17.558,06-	USD
<input type="checkbox"/> 100008840	31.12.2009	31.12.2009	2009/12	SA	TS1209_COMM CORR	404030	OXY	Correct commission for Aug 09	590,08	USD
<input type="checkbox"/> 100009889	30.09.2010	30.09.2010	2010/09	SA	TS0910_TOTCOMM	404030	ORF		28.609,09-	USD
<input type="checkbox"/> 100010050	31.10.2010	31.10.2010	2010/10	SA	TS1010_TOT COMM	404030	ORF	Totowa commission Oct	93.690,44-	USD
<input type="checkbox"/> 100011127	31.05.2011	31.05.2011	2011/05	SA	TS0511_TOTOWA CO	404030	ORF		32.426,15-	USD
<input type="checkbox"/> 100011920	31.12.2011	31.12.2011	2011/12	SA	TS1211_TOTOWA CO	404030	ORF		34.201,87-	USD
<input type="checkbox"/> 100012627	30.06.2012	05.07.2012	2012/06	SA	JAS20120609	404030	ORF	10% commisson on Totowa June Production	23.791,65-	USD
<input type="checkbox"/> 100013041	31.10.2012	05.11.2012	2012/10	SA	JAS20121006	404030	ORF	10% commisson on Totowa June Production	14.337,76-	USD
<input type="checkbox"/> 100013760	31.05.2013	04.06.2013	2013/05	SA	JAS20130506	404030	ORF	Commission for Totowa May production of ORF	21.744,38-	USD
<input type="checkbox"/> 100015113	30.09.2014	30.09.2014	2014/09	SA	JC0914_TOTOWA CO	404030	ORF	Commission for Totowa Sept production of ORF	27.768,96-	USD
<input type="checkbox"/>									1.700.907,13-	USD

Note:

- The SAP screenshot does not include all entries – excerpt version shown.

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

According to P.F. Labs's accounting records in SAP, transactions related to the CMO services were recognized as follows in P.F. Labs' (SAP company code 109) accounting records (2014 is illustrated below).

Account Number	Account Description	DR	CR
Manufacturing costs:			
503000	Cost of Goods Standard - Manufacturing	\$ 277,690	
404000	Gross Sales - Manufacturing		\$ (277,690)
Sales commissions:			
102208	Purdue Pharma L.P.	\$ 27,769	
404030	Sales Commission		\$ (27,769)
Intercompany recognition:			
102208	Purdue Pharma L.P.	\$ 277,690	
102999	Virtual Company		\$ (277,690)

Note:

- G/L account 102999 – Virtual Company is a pooling account for sweep entries before allocating amounts to specific companies.

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

These entries appear in P.F. Labs's accounting records in SAP as follows (2014 is illustrated below, the last year of the manufacturing agreement).

Manufacturing costs:

Doc.Type : ZG (G/L acct doc Sweep) Normal document				
Doc. Number	100015097	Company Code	109	Fiscal Year 2014
Doc. Date	02.10.2014	Posting Date	30.09.2014	Period 09
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	XXX	Overall No.	0100015097109 14	
Doc. Currency	USD			
Doc. Hdr Text	Mfg Sweep Entry 09 2014			

Itm	PK	Account	Account short text	Amount	Text
1	50	501021	Prod Var Reclass	3.855,85-	Mfg Variance-109 Mfg Sweep Entry 09 2014
2	40	102999	Virtual Company	3.855,85	Mfg Variance-109 Mfg Sweep Entry 09 2014
3	40	503000	COGs std MFG	277.689,56	F output to Mfg Mfg Sweep Entry 09 2014
4	50	404000	Gross Sales MFG	277.689,56-	F output to Mfg Mfg Sweep Entry 09 2014

10% markup:

Doc.Type : SA (G/L account document) Normal document				
Doc. Number	100015113	Company Code	109	Fiscal Year 2014
Doc. Date	30.09.2014	Posting Date	30.09.2014	Period 09
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	JC0914_TOTOWA CG	Overall No.	0100138628208 14	
Doc. Currency	USD			
Doc. Hdr Text	Totowa ORF Commission Sep			

Itm	PK	Account	Account short text	Amount	Text
1	50	404030	Sales Commission	27.768,96-	Commission for Totowa Sept production of ORF
2	40	102208	Purdue Pharma L.P.	27.768,96	

Intercompany recognition:

Doc.Type : ZG (G/L acct doc Sweep) Normal document					
Doc. Number	100015125	Company Code	109	Fiscal Year	2014
Doc. Date	08.10.2014	Posting Date	30.09.2014	Period	09
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	XXX	Overall No.	0100027587307 14		
Doc. Currency	USD				
Doc. Hdr Text	Dist Sweep Entry 09 2014				

Itm	FK	Account	Account short text	Amount	Text
1	50	102999	Virtual Company	277.689,56-	QC sample offset Dist Sweep Entry 09 2014
2	40	102208	Purdue Pharma L.P.	277.689,56	QC sample offset Dist Sweep Entry 09 2014

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

These entries appear in the P.F. Labs accounting records in SAP as follows (2008, the first payment in the time period reviewed, is illustrated below).

Manufacturing costs:

Doc.Type : ZG (G/L acct doc Sweep) Normal document					
Doc. Number	100004430	Company Code	109	Fiscal Year	2008
Doc. Date	04.02.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	XXX	Overall No.	0100004430109 08		
Doc. Currency	USD				
Doc. Hdr Text	Mfg Sweep Entry 01 2008				

Itm	PK	Account	Account short text	Amount	Text
1	40	501021	Prod Var Reclass	109.173,70	Mfg Variance-109 Mfg Sweep Entry 01 2008
2	40	501021	Prod Var Reclass	148,67	Mfg Variance-109 Mfg Sweep Entry 01 2008
3	50	102999	Virtual Company	109.173,70-	Mfg Variance-109 Mfg Sweep Entry 01 2008
4	50	102999	Virtual Company	148,67-	Mfg Variance-109 Mfg Sweep Entry 01 2008
5	40	503000	COGS std MFG	465.830,88	F output to Mfg Mfg Sweep Entry 01 2008
6	40	503000	COGS std MFG	98.132,79	F output to Mfg Mfg Sweep Entry 01 2008
7	50	404000	Gross Sales MFG	465.830,88-	F output to Mfg Mfg Sweep Entry 01 2008
8	50	404000	Gross Sales MFG	98.132,79-	F output to Mfg Mfg Sweep Entry 01 2008

10% markup:

Doc.Type : SA (G/L account document) Normal document					
Doc. Number	100004421	Company Code	109	Fiscal Year	2008
Doc. Date	31.01.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	TS0108_TOI 10%	Overall No.	0100032348208 08		
Doc. Currency	USD				
Doc. Hdr Text	Totowa commission				

Itm	PK	Account	Account short text	Tx	Amount	Text
1	50	404030	Sales Commission		46.583,09-	Totowa Commission 0108
2	50	404030	Sales Commission		9.813,28-	Totowa Commission 0108
3	40	102208	Purdue Pharma L.P.		56.396,37	Totowa Commission 0108

Intercompany recognition:

Doc.Type : ZG (G/L acct doc Sweep) Normal document					
Doc. Number	100004451	Company Code	109	Fiscal Year	2008
Doc. Date	06.02.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	XXX	Overall No.	0100032410208 08		
Doc. Currency	USD				
Doc. Hdr Text	Dist Sweep Entry 01 2008				

Itm	PK	Account	Account short text	Amount	Text
1	50	102999	Virtual Company	465.830,88-	QC sample offset Dist Sweep Entry 01 2008
2	50	102999	Virtual Company	98.132,79-	QC sample offset Dist Sweep Entry 01 2008
3	40	102208	Purdue Pharma L.P.	465.830,88	QC sample offset Dist Sweep Entry 01 2008
4	40	102208	Purdue Pharma L.P.	98.132,79	QC sample offset Dist Sweep Entry 01 2008

Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

The transactions related to CMO services were not settled with individual cash payments.

Based on a preliminary analysis of the intercompany account (102208 Purdue Pharma L.P.) in P.F. Labs's accounting records in SAP (SAP company code 109), the balance of the account appears to have been settled on a regular basis.

Furthermore, there were regular cash payments from PPLP, which were in excess of the charges related to the CMO services.

Account 102208-109	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Prior Year Cumulative Balance	\$ (13,691,651)	\$ (11,186,932)	\$ (3,919,783)	\$ (4,157,573)	\$ (2,984,902)	\$ 1,552,237	\$ 3,502,008	\$ 6,590,556	\$ 6,150,606	\$ 5,510,519	\$ 6,988,497	\$ (994,878)	
Debits	42,637,294	66,215,261	28,853,185	31,669,646	26,126,457	29,611,533	13,882,859	12,763,040	3,754,677	1,900,759	78,083	997,132	258,489,927
Credits	(40,132,575)	(58,948,112)	(29,090,975)	(30,496,976)	(21,589,318)	(27,661,761)	(10,794,311)	(13,202,991)	(4,394,764)	(422,781)	(8,061,459)	(6,695)	(244,802,718)
Ending Cumulative Balance	\$ (11,186,932)	\$ (3,919,783)	\$ (4,157,573)	\$ (2,984,902)	\$ 1,552,237	\$ 3,502,008	\$ 6,590,556	\$ 6,150,606	\$ 5,510,519	\$ 6,988,497	\$ (994,878)	\$ (4,442)	
CMO Charges	\$ 10,794,832	\$ 3,798,172	\$ 1,222,995	\$ 666,280	\$ 381,294	\$ 217,444	\$ 277,690	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 17,358,707
Shared Services Charges	2,072,026	1,087,225	2,443,501	1,518,498	1,737,076	1,514,823	426,056	-	2,199,788	-	-	-	12,998,994
Intercompany Consolidation Entries	4,281,830	3,926,653	2,262,639	6,776,819	4,249,483	7,405,265	2,302,333	357,900	403,415	1,559,592	3,090	-	33,529,019
Production Variance Entries	21,033,300	25,387,000	20,247,700	18,509,700	19,408,500	20,154,200	9,178,600	-	-	-	-	-	133,919,000
Correcting Entries	-	23,955,950	-	1,450	50	-	-	-	-	-	-	-	23,957,450
Cash to PPLP	503,000	685,000	-	-	-	-	-	-	1,000,000	-	40,093	997,132	3,225,225
Other Debits ¹	3,952,306	7,375,262	2,676,349	4,196,899	350,054	319,801	1,698,180	12,405,140	151,474	341,168	34,900	-	33,501,532
Total Debits	\$ 42,637,294	\$ 66,215,261	\$ 28,853,185	\$ 31,669,646	\$ 26,126,457	\$ 29,611,533	\$ 13,882,859	\$ 12,763,040	\$ 3,754,677	\$ 1,900,759	\$ 78,083	\$ 997,132	\$ 258,489,927
Intercompany Consolidation Entries	\$ (5,002,495)	\$ (3,367,354)	\$ (3,050,393)	\$ (4,154,123)	\$ (1,972,012)	\$ (5,915,669)	\$ (1,228,237)	\$ (468,234)	\$ (415,707)	\$ (39,726)	\$ (3,347)	\$ -	\$ (25,617,298)
Production Variance Entries	(813,000)	-	(2,478,300)	(2,787,400)	(3,647,700)	(4,449,500)	(892,300)	-	-	-	-	-	(15,068,200)
Intercompany Charges / Shared Services	(2,069,871)	(3,905,640)	(3,754,480)	(1,963,387)	(2,944,526)	(3,240,348)	(77,493)	(195,964)	(1,221,429)	(90,827)	(11,433)	-	(19,475,400)
Intercompany Reclassification Entries	-	(24,677,176)	-	-	-	-	-	-	-	-	-	-	(24,677,176)
Cash from PPLP	(25,530,600)	(21,541,046)	(16,887,000)	(16,705,003)	(10,750,000)	(11,768,000)	(6,455,000)	(5,375,000)	(500,000)	-	(6,987,465)	-	(122,499,113)
Other Credits ¹	(6,716,609)	(5,456,896)	(2,920,801)	(4,887,063)	(2,275,080)	(2,288,244)	(2,141,281)	(7,163,793)	(2,257,628)	(292,227)	(1,059,214)	(6,695)	(37,465,531)
Total Credits	\$ (40,132,575)	\$ (58,948,112)	\$ (29,090,975)	\$ (30,496,976)	\$ (21,589,318)	\$ (27,661,761)	\$ (10,794,311)	\$ (13,202,991)	\$ (4,394,764)	\$ (422,781)	\$ (8,061,459)	\$ (6,695)	\$ (244,802,718)

¹ "Other Debits" and "Other Credits" consist of intercompany interest as well as various other journal entries. Analysis of these entries remains ongoing.

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

On April 13, 1998, Purdue entered into a service agreement with Terramar for office space. Pursuant to the service agreement, Purdue agreed to pay rent calculated as costs (i.e. "Expenses") plus 10%.

SERVICE AGREEMENT

SERVICE AGREEMENT, effective as of April 13, 1998
between The Terramar Foundation, Inc., a Delaware corpora-
tion ("Terramar"), and Purdue Pharma L.P., a Delaware
limited partnership ("PPLP"),

W I T N E S S E T H :

WHEREAS, Terramar desires to provide facilities and
services to PPLP at Terramar's offices at [REDACTED]
[REDACTED], New York, New York; and

WHEREAS, PPLP is willing to pay for such facilities
and services provided by Terramar to PPLP;

NOW, THEREFORE, it is agreed as follows:

1. PPLP will pay for services hereunder in an
amount equal to Expenses (as defined herein) plus 10% of
Expenses.

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Pursuant to the service agreement, Expenses included the following:

2. "Expenses" means the costs and expenses incurred by Terramar on behalf of or for PPLP and associated with each of the following:

- (a) salaries of Terramar personnel whose activities include activities undertaken on behalf of PPLP;
- (b) employee benefits, payroll taxes and such other employment taxes as may be applicable with respect to the personnel identified in paragraph 2(a) above;

(c) fees for general legal services and advice specific to the conduct of the activities undertaken by Terramar on behalf of PPLP;

- (d) travel and representation;
- (e) rent and service fees for facilities and equipment;
- (f) telecommunications;
- (g) postage, stationery and supplies;
- (h) financial and trade journals; and
- (i) other office overhead expenses associated with services and facilities provided by Terramar to PPLP; and
- (j) all sales, use and occupancy taxes on the above.

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Between January 31, 2008 and July 31, 2018, Purdue Pharma L.P. was charged approximately \$22.2 million in office space rent by Terramar. The agreement terminated as of July 1, 2018.

Year	Charges for Costs & Expenses		Service Charge	Total
2008	\$	1,443,581	\$ 144,358	\$ 1,587,939
2009		1,671,798	167,180	1,838,978
2010		1,576,459	157,646	1,734,105
2011		1,850,762	185,076	2,035,838
2012		1,788,067	178,807	1,966,874
2013		2,489,028	248,903	2,737,930
2014		2,137,612	213,761	2,351,373
2015		1,998,502	199,850	2,198,353
2016		2,100,172	210,017	2,310,189
2017		2,045,599	204,560	2,250,159
2018		1,077,073	107,575	1,184,648
Total	\$	20,178,653	\$ 2,017,733	\$ 22,196,386

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

According to Terramar's accounting records in SAP, Terramar (SAP company code 504) charged Purdue for office space through G/L account 690100 (InterCo Charges/Credits). The screenshot below illustrates the last few years of rent, including total rent and service charges of \$22.2 million charged to Purdue since 2008.

G/L Account Line Item Display														
G/L Account 690100 InterCo Charges/Credits Company Code 504														
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	504	100003152	30.04.2016	05.05.2016	4	2016/04	SA	2100504	EL 050516 52	690100	GEN	Reclass Terramar expense April 2016	157.736,56-	USD
<input type="checkbox"/>	504	100003177	31.05.2016	06.06.2016	5	2016/05	SA	2100504	EL 060616 40	690100	GEN	Reclass Terramar expense May 2016	248.803,63-	USD
<input type="checkbox"/>	504	100003205	30.06.2016	07.07.2016	6	2016/06	SA	2100504	EL 070716 43	690100	GEN	Reclass Terramar expense June 2016	181.979,34-	USD
<input type="checkbox"/>	504	100003233	31.07.2016	04.08.2016	7	2016/07	SA	2100504	EL 080416 46	690100	GEN	Reclass Terramar expense July 2016	185.604,62-	USD
<input type="checkbox"/>	504	100003257	31.08.2016	07.09.2016	8	2016/08	SA	2100504	EL 090716 46	690100	GEN	Reclass Terramar expense August 2016	187.191,37-	USD
<input type="checkbox"/>	504	100003284	30.09.2016	10.10.2016	9	2016/09	SA	2100504	EL 101016 55	690100	GEN	Reclass Terramar expense Sept 2016	176.158,74-	USD
<input type="checkbox"/>	504	100003311	31.10.2016	03.11.2016	10	2016/10	SA	2100504	EL 110316 41	690100	GEN	Reclass Terramar expense Oct 2016	174.717,98-	USD
<input type="checkbox"/>	504	100003340	30.11.2016	06.12.2016	11	2016/11	SA	2100504	EL 120616 40	690100	GEN	Reclass Terramar expense Nov 2016	177.135,05-	USD
<input type="checkbox"/>	504	100003391	31.12.2016	23.01.2017	12	2016/12	SA	2100504	EL 012317 70	690100	GEN	Reclass Terramar expense Dec 2016	304.468,18-	USD
<input type="checkbox"/>	504	100003416	31.12.2016	16.02.2017	12	2016/12	SA	2100504	EL 021617 83	690100	GEN	Reclass Terramar expense Dec 2016	8.788,70-	USD
<input type="checkbox"/>	504	100003417	31.01.2017	21.02.2017	1	2017/01	SA	2100504	EL 022117 42	690100	GEN	Reclass Terramar expense Jan 2017	145.929,81-	USD
<input type="checkbox"/>	504	100003442	28.02.2017	06.03.2017	2	2017/02	SA	2100504	EL 030617 37	690100	GEN	Reclass Terramar expense Feb 2017	182.954,71-	USD
<input type="checkbox"/>	504	100003471	31.03.2017	06.04.2017	3	2017/03	SA	2100504	EL 040617 48	690100	GEN	Reclass Terramar expense March 2017	159.764,66-	USD
<input type="checkbox"/>	504	100003502	30.04.2017	04.05.2017	4	2017/04	SA	2100504	EL 050417 37	690100	GEN	Reclass Terramar expense April 2017	246.810,27-	USD
<input type="checkbox"/>	504	100003528	31.05.2017	05.06.2017	5	2017/05	SA	2100504	HS 0517	690100	GEN	Reclass Terramar expense May 2017	193.961,33-	USD
<input type="checkbox"/>	504	100003548	30.06.2017	04.07.2017	6	2017/06	SA	2100504	HS 0617	690100	GEN	Reclass Terramar expense June 2017	208.627,57-	USD
<input type="checkbox"/>	504	100003580	31.07.2017	04.08.2017	7	2017/07	SA	2100504	HS 0717	690100	GEN	Reclass Terramar expense July 2017	190.375,70-	USD
<input type="checkbox"/>	504	100003610	31.08.2017	07.09.2017	8	2017/08	SA	2100504	HS 0817	690100	GEN	Reclass Terramar expense August 2017	188.631,41-	USD
<input type="checkbox"/>	504	100003647	30.09.2017	05.10.2017	9	2017/09	SA	2100504	HS 0917	690100	GEN	Reclass Terramar expense September 2017	168.649,99-	USD
<input type="checkbox"/>	504	100003677	31.10.2017	07.11.2017	10	2017/10	SA	2100504	HS 1017	690100	GEN	Reclass Terramar expense October 2017	166.550,69-	USD
<input type="checkbox"/>	504	100003701	30.11.2017	06.12.2017	11	2017/11	SA	2100504	HS 1117	690100	GEN	Reclass Terramar expense November 2017	230.315,31-	USD
<input type="checkbox"/>	504	100003729	31.12.2017	15.01.2018	12	2017/12	SA	2100504	HS 1217	690100	GEN	Reclass Terramar expense December 2017	210.656,41-	USD
<input type="checkbox"/>	504	100003753	31.12.2017	25.01.2018	12	2017/12	SA	2100504	HS 1217	690100	GEN	Reclass Terramar expense December 2017	43.068,52	USD
<input type="checkbox"/>	504	100003791	31.01.2018	23.02.2018	1	2018/01	SA	2100504	HS 0118	690100	GEN	Reclass Terramar expense January 2018	186.564,29-	USD
<input type="checkbox"/>	504	100003814	28.02.2018	06.03.2018	2	2018/02	SA	2100504	HS 0218	690100	GEN	Reclass Terramar expense February 2018	179.388,73-	USD
<input type="checkbox"/>	504	100003841	31.03.2018	06.04.2018	3	2018/03	SA	2100504	HS 0318	690100	GEN	#REF!	195.599,45-	USD
<input type="checkbox"/>	504	100003868	30.04.2018	04.05.2018	4	2018/04	SA	2100504	RB 0418	690100	GEN	Reclass Terramar expense April 2018	186.384,07-	USD
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA	2100504		690100	GEN	Reclass Terramar May 2018	216.856,27-	USD
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA	2100504		690100	GEN	Reclass Terramar June 2018	219.855,89-	USD
*												22.196.386,24-	USD	

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Per Purdue's internal analysis of office space charges, the amount that Terramar charged to Purdue for office space was recorded as cost plus a 10% service charge.

A 2018 internal analysis (shown below) shows \$1.2 million in rent billed from Terramar, which reconciles to SAP.

2018	JAN	FEB	MAR	APRIL	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	TOTAL
Terramar (504) To PPLP (208)													
Trial Bal	169,604	163,081	177,817	169,440	197,142	199,989							1,077,073
ID Less Items not Billed													0
608461 Legal 608461 Corp Litigation	-	-	-	-	-	-	-						0
608470 Legal 608470 Legal Other	-	-	-	-	-	-	-						0
608450 Acct Fees External HS 608450	-	-	-	-	-	-	-						0
640000 Contributions 640000	-	-	-	-	-	-	-						0
611615 Community Rel Supp. 611615	-	-	-	-	-	-	-						0
800400 Federal Taxes 800400	-	-	-	-	-	-	-						0
800401 Federal Taxes current year 800401	-	-	-	-	-	-	-						0
800405 State Taxes 800405	-	-	-	-	-	-	-						0
800407 State Taxes current year 800407	-	-	-	-	-	-	-						0
Prior period adj & Fixed Asset adj													0
Adjusted Total	169,603.90	163,080.66	177,817.00	169,440.00	197,142.00	199,989.00	-	-	-	-	-	-	1,077,072.56
Mark-Up 10%	16,960.39	16,308.07	17,781.70	16,944.00	19,714.20	19,867.00			0.00	0.00	0.00	0.00	107,575.36
TOTAL BILLING	186,564.29	179,388.73	195,598.70	186,384.00	216,856.20	219,856.00	0.00	0.00	0.00	0.00	0.00	0.00	1,184,648
504-690100-2100504 Credit													
504-102208 Debit													
208-690100-2100208 DEBIT													
208-102504 CREDIT													

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

According to SAP, Terramar (SAP company code 504) charged Purdue \$1.6 and \$1.2 million for office space in 2008 and 2018, respectively, through G/L account 690100 (InterCo Charges/Credits).

G/L Account		690100	InterCo Charges/Credits											
Company Code		504												
	CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	504	100000580	31.01.2008	20.02.2008	1	2008/01	SA	2100504	EL 22008 20	690100	GEN	Reclass Terramar expense to PFLP Jan 08	106.981,85-	USD
<input type="checkbox"/>	504	100000601	29.02.2008	06.03.2008	2	2008/02	SA	2100504	CK 030608 TR	690100	GEN	Reclass Terramar expense to PFLP Feb 08	119.786,61-	USD
<input type="checkbox"/>	504	100000625	31.03.2008	03.04.2008	3	2008/03	SA	2100504	CK 040308 TR	690100	GEN	Reclass Terramar expense to PFLP Mar 08	138.954,78-	USD
<input type="checkbox"/>	504	100000646	30.04.2008	06.05.2008	4	2008/04	SA	2100504	CK 050608 TR	690100	GEN	Reclass Terramar expense to PFLP Apr 08	105.546,68-	USD
<input type="checkbox"/>	504	100000665	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16-	USD
<input type="checkbox"/>	504	100000666	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16-	USD
<input type="checkbox"/>	504	100000667	03.06.2008	03.06.2008	6	2008/06	AB	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16	USD
<input type="checkbox"/>	504	100000668	30.06.2008	03.06.2008	6	2008/06	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16-	USD
<input type="checkbox"/>	504	100000669	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR CR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16	USD
<input type="checkbox"/>	504	100000691	30.06.2008	03.07.2008	6	2008/06	SA	2100504	CK 070308 TR	690100	GEN	Reclass Terramar expense to PFLP June 08	161.849,77-	USD
<input type="checkbox"/>	504	100000711	31.07.2008	06.08.2008	7	2008/07	SA	2100504	CK 073108 TR	690100	GEN	Reclass Terramar expense to PFLP July 08	123.835,44-	USD
<input type="checkbox"/>	504	100000729	29.08.2008	05.09.2008	8	2008/08	SA	2100504	CK 082908 TR	690100	GEN	Reclass Terramar expense to PFLP Aug 08	129.353,13-	USD
<input type="checkbox"/>	504	100000751	30.09.2008	06.10.2008	9	2008/09	SA	2100504	CK 093008 TR	690100	GEN	Reclass Terramar expense to PFLP Sep 08	123.709,92-	USD
<input type="checkbox"/>	504	100000765	31.10.2008	05.11.2008	10	2008/10	SA	2100504	CK 103108 TR	690100	GEN	Reclass Terramar expense to PFLP Oct 08	147.334,35-	USD
<input type="checkbox"/>	504	100000781	26.11.2008	03.12.2008	11	2008/11	SA	2100504	CK 112608 TR	690100	GEN	Reclass Terramar expense to PFLP Nov 08	124.657,04-	USD
<input type="checkbox"/>	504	100000823	31.12.2008	27.01.2009	12	2008/12	SA	2100504	CK 123108 TR	690100	GEN	Reclass Terramar expense to PFLP Dec 08	177.450,66-	USD
<input type="checkbox"/>	*												1.587.939,39-	USD

G/L Account Line Item Display

Navigation icons: Back, Forward, Home, Search, Print, etc.

G/L Account
Company Code

690100

InterCo Charges/Credits

504

CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	504	100003791	31.01.2018	23.02.2018	1	2018/01	SA	2100504	HS 0118	690100	GEN	Reclass Terramar expense January 2018	186.564,29-	USD
<input type="checkbox"/>	504	100003814	28.02.2018	06.03.2018	2	2018/02	SA	2100504	HS 0218	690100	GEN	Reclass Terramar expense February 2018	179.388,73-	USD
<input type="checkbox"/>	504	100003841	31.03.2018	06.04.2018	3	2018/03	SA	2100504	HS 0318	690100	GEN	#REF!	195.599,45-	USD
<input type="checkbox"/>	504	100003868	30.04.2018	04.05.2018	4	2018/04	SA	2100504	RB 0418	690100	GEN	Reclass Terramar expense April 2018	186.384,07-	USD
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA	2100504		690100	GEN	Reclass Terramar May 2018	216.856,27-	USD
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA	2100504		690100	GEN	Reclass Terramar June 2018	219.855,89-	USD
<input type="checkbox"/>	*											1.184.648,70-	USD	

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Cash payments were recognized as follows on Purdue Pharma L.P.'s books (SAP company code 208). The July 2018 cash payment is illustrated below.


Company	Account Number	Account Description	DR	CR
208	100010	Cash Concentration		\$ (943,039)
208	102504	Terramar Foundation	\$ 943,039	
504	100010	Cash Concentration	\$ 943,039	
504	102208	Purdue Pharma L.P.		\$ (943,039)

208: Purdue Pharma L.P.

504: Terramar Foundation Inc.

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Terramar (SAP company code 504) charged Purdue through G/L account 102208. The balance in the account accrued, but was partially paid off periodically such that the cumulative balance never exceeded \$1 million. The July 2018 cash payment from PPLP to Terramar is illustrated below as it closed all activity relating to office space payments.¹

Account number	102208	Purdue Pharma L.P.		
Company code	504	Terramar Foundation, Inc.		
Business area				
Fiscal year	2018			
All documents in currency	*	Display currency USD		
				
Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				826.722,45
1	193.199,88	151.460,61	41.739,27	868.461,72
2	182.918,63	139.006,92	43.911,71	912.373,43
3	196.030,31	266.224,39	70.194,08-	842.179,35
4	215.394,49	157.576,44	57.818,05	899.997,40
5	219.251,19	176.209,82	43.041,37	943.038,77
6	908.732,12	1.101.820,66	193.088,54-	749.950,23
7	243.630,39	1.062.752,66	819.122,27-	69.172,04-
8	25.000,00	422.154,81	397.154,81-	466.326,85-
9	41.693,01	21.646,80	20.046,21	446.280,64-
10		14.849,22	14.849,22-	461.129,86-
11		65.269,29	65.269,29-	526.399,15-
12	215.722,64	124.566,54	91.156,10	435.243,05-
13				435.243,05-
14				435.243,05-
15				435.243,05-
16				435.243,05-
Total	2.441.572,66	3.703.538,16	1.261.965,50-	435.243,05-

G/L Account		102208	Purdue Pharma L.P.							
Company Code		504								
tng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
07.2018	01.06.2018	7	2018/07	RE		060118B	102208	GEN		358,66-
07.2018	06.06.2018	7	2018/07	RE		2313057	102208	GEN		404,73-
07.2018	11.06.2018	7	2018/07	RE		C0045369280	102208	GEN		38,77-
07.2018	30.06.2018	7	2018/07	RE		100750526	102208	GEN		1.693,92-
07.2018	06.07.2018	7	2018/07	RE		S053910061	102208	GEN		1.433,82-
07.2018	09.07.2018	7	2018/07	SA		CWS	102208	GEN		943.038,77-
07.2018	10.07.2018	7	2018/07	RE		C0045447514	102208	GEN		38,77-
07.2018	13.07.2018	7	2018/07	KR		JBS071318	102208	GEN		4.638,62-
07.2018	13.07.2018	7	2018/07	KR		CABRALD071318	102208	GEN		101,92-
07.2018	26.07.2018	7	2018/07	SA		LT 0718	102208	GEN		6.250,00-
07.2018	26.07.2018	7	2018/07	SA		EL 072618 9	102208	GEN		75.000,00-
07.2018	27.07.2018	7	2018/07	SA			102208	GEN		389,00-
07.2018	27.07.2018	7	2018/07	KR		JBS072718	102208	GEN		3.944,83-
07.2018	27.07.2018	7	2018/07	KR		CABRALD072718	102208	GEN		101,92-
07.2018	31.07.2018	7	2018/07	RC			102208	GEN	Reconciliation Posting CO	430,86-
07.2018	31.07.2018	7	2018/07	SA		EXPENSITE EXP	102208	GEN		11.050,38-
07.2018	01.08.2018	7	2018/07	SA		LT 718	102208	GEN	To rec adj for Retirement Admin Fee - July	115,00-
07.2018	02.08.2018	7	2018/07	SA		LMT 718	102208	GEN		7.236,45-
07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Medical Charges	4.529,05-
07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Dental Charges	639,39-
07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Drug Charges	1.322,80-
*										1.062.752,66-

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK	Account	Account short text	Assignment	Tx	Amount	Text
208	100175718	2018	SA	09.07.2018	08.07.2018	CWS	USD
1	50	100010	Cash Concentration	20180709		943.038,77-	CORP PAY
2	40	102504	Terramar Foundation	20180709		943.038,77	
504	100003945	2018	SA	09.07.2018	08.07.2018	CWS	USD
1	40	100010	Cash Concentration	20180709		943.038,77	CORP PAY
2	40	100010	Cash Concentration	20180709		777,00	00000000932902583 REFOCUS FOUNDATION INC. 15 E 62H
3	50	101040	A/R Clearing (Trade)	20180709		777,00-	00000000932902583 REFOCUS FOUNDATION INC. 15 E 62H
4	50	102208	Purdue Pharma L.P.	20180709		943.038,77-	

¹Per Purdue, PPLP settled to cash partial amounts of the outstanding account activity in June and July 2018 for identical amounts: \$943,038.77

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

SAP contains support for the May and June 2018 rent charges to PPLP that was settled as part of the July 2018 payment.

G/L Account		102208		Purdue Pharma L.P.									
Company Code		504											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	504	100003911	31.05.2018	31.05.2018	5	2018/05	SA	EXPENSITE EXP	102208	GEN		4.481,37-	USD
<input type="checkbox"/>	504	100003912	31.05.2018	31.05.2018	5	2018/05	RC		102208	GEN	Reconciliation Posting CO	430,86-	USD
<input type="checkbox"/>	504	100003913	31.12.2017	01.06.2018	12	2017/12	SA	RK 1217 33	102208	GEN	LCD 12.31.2017	55.449,46-	USD
<input type="checkbox"/>	504	100003909	31.05.2018	01.06.2018	5	2018/05	SA	CWS	102208	GEN		77.605,75-	USD
<input type="checkbox"/>	504	1900005737	01.06.2018	01.06.2018	6	2018/06	KR	JBS060118	102208	GEN		5.069,94-	USD
<input type="checkbox"/>	504	1900005738	01.06.2018	01.06.2018	6	2018/06	KR	CABRALD060118	102208	GEN		101,92-	USD
<input type="checkbox"/>	504	100003915	03.06.2018	04.06.2018	6	2018/06	SA	CWS	102208	GEN		1.099,24-	USD
<input type="checkbox"/>	504	100003917	31.05.2018	05.06.2018	5	2018/05	SA	LMT 518	102208	GEN		2.607,84-	USD
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA		102208	GEN		216.856,27	USD
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	73,90	USD
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	0,76-	USD
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	26,35-	USD
<input type="checkbox"/>	504	100003921	10.06.2018	11.06.2018	6	2018/06	SA	CWS	102208	GEN		17,74-	USD
<input type="checkbox"/>	504	1900005740	15.06.2018	15.06.2018	6	2018/06	KR	JBS061518	102208	GEN		5.039,48-	USD
<input type="checkbox"/>	504	1900005745	15.06.2018	15.06.2018	6	2018/06	KR	CABRALD061518	102208	GEN		101,92-	USD
<input type="checkbox"/>	504	100003923	17.06.2018	18.06.2018	6	2018/06	SA	CWS	102208	GEN		27.211,17-	USD
<input type="checkbox"/>	504	100003925	24.06.2018	25.06.2018	6	2018/06	SA	CWS	102208	GEN		9.910,67-	USD
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Medical Charges	4.528,05-	USD
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Dental Charges	635,39-	USD
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Drug Charges	1.322,80-	USD
<input type="checkbox"/>	504	100003928	27.06.2018	28.06.2018	6	2018/06	SA	CWS	102208	GEN		651.376,23	USD
<input type="checkbox"/>	504	100003929	27.06.2018	28.06.2018	6	2018/06	SA	CWS	102208	GEN		943.038,77-	USD
<input type="checkbox"/>	504	100003930	29.06.2018	29.06.2018	6	2018/06	SA		102208	GEN		389,00-	USD
<input type="checkbox"/>	504	1900005743	29.06.2018	29.06.2018	6	2018/06	KR	JBS062918	102208	GEN		5.083,62-	USD
<input type="checkbox"/>	504	1900005744	29.06.2018	29.06.2018	6	2018/06	KR	CABRALD062918	102208	GEN		101,92-	USD
<input type="checkbox"/>	504	100003936	30.06.2018	30.06.2018	6	2018/06	RC		102208	GEN	Reconciliation Posting CO	430,86-	USD
<input type="checkbox"/>	504	100003937	30.06.2018	30.06.2018	6	2018/06	SA	EXPENSITE EXP	102208	GEN		803,64-	USD
<input type="checkbox"/>	504	100003934	30.06.2018	02.07.2018	6	2018/06	SA	CWS	102208	GEN		25.616,88-	USD
<input type="checkbox"/>	504	100003943	30.06.2018	02.07.2018	6	2018/06	SA	LT 618	102208	GEN	To rec adj for Retirement Admin Fee - June	115,00-	USD
<input type="checkbox"/>	504	100003938	30.06.2018	03.07.2018	6	2018/06	SA	LMT 618	102208	GEN		32.068,32-	USD
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA		102208	GEN		219.855,89	USD
<input type="checkbox"/>	504	100003948	30.06.2018	11.07.2018	6	2018/06	SA	EL 071118 36	102208	GEN		37.500,00-	USD
<input type="checkbox"/>	504	100003949	30.06.2018	11.07.2018	6	2018/06	SA	EL 071118 37	102208	GEN		37.500,00	USD
<input type="checkbox"/>	504	1700000042	15.09.2003	05.06.2149	9	2003/09	KA	77	102208	GEN		395,34	USD
<input type="checkbox"/>	504	1900001022	15.09.2003	05.06.2149	9	2003/09	KR	77	102208	GEN		395,34-	USD
<input type="checkbox"/>	504	1700000043	01.10.2003	14.08.2151	10	2003/10	KA	10A0465029	102208	GEN		155,04	USD
<input type="checkbox"/>	504	1900001028	01.10.2003	14.08.2151	10	2003/10	KR	10A0465029	102208	GEN		155,04-	USD
<input type="checkbox"/>	*											749.950,23	USD

Note: PPLP also provided cash payments to various entities for charges relating to insurance, fleet expenses, pensions, travel and entertainment, etc. Per discussions with Purdue, no formal agreements exist for these arrangements. Charges/cash payments for these other items represent the remaining portion of the activity in PPLP's account (102208) in Terramar's books (SAP company code 504).

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Rent charges and payments can be observed in the G/L account activity of account 102208 on Terramar's books (SAP company code 504). The debits to the account (consisting mostly of rent charges) are netted by credit entries (consisting mostly of cash payments) that result in a relatively low cumulative account balance.

Account 102208-504	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ 260,091	\$ 562,179	\$ 621,822	\$ 710,642	\$ 874,613	\$ 1,041,022	\$ 341,723	\$ 298,964	\$ 544,559	\$ 807,406	\$ 826,722	\$ (435,243)	
Debits	2,200,268	1,898,269	1,795,581	2,133,488	2,172,940	2,914,298	2,561,180	2,303,609	2,626,039	2,443,581	2,441,573	562,783	26,053,609
Credits	(1,898,180)	(1,838,625)	(1,706,761)	(1,969,517)	(2,006,531)	(3,613,597)	(2,603,939)	(2,058,014)	(2,363,192)	(2,424,265)	(3,703,538)	(160,012)	(26,346,172)
Ending Cumulative Balance	\$ 562,179	\$ 621,822	\$ 710,642	\$ 874,613	\$ 1,041,022	\$ 341,723	\$ 298,964	\$ 544,559	\$ 807,406	\$ 826,722	\$ (435,243)	\$ (32,472)	
Rent Charges	\$ 1,587,939	\$ 1,838,978	\$ 1,734,105	\$ 2,035,838	\$ 1,966,874	\$ 2,737,930	\$ 2,351,373	\$ 2,198,353	\$ 2,310,188	\$ 2,250,159	\$ 1,184,649	\$ -	\$ 22,196,386
Other Non-Rent Debits	612,329	59,291	61,476	97,650	206,067	176,368	209,807	105,256	315,851	193,422	1,256,924	562,783	3,857,223
Total Debits	\$ 2,200,268	\$ 1,898,269	\$ 1,795,581	\$ 2,133,488	\$ 2,172,940	\$ 2,914,298	\$ 2,561,180	\$ 2,303,609	\$ 2,626,039	\$ 2,443,581	\$ 2,441,573	\$ 562,783	\$ 26,053,609
Cash Payments	\$ (1,449,529)	\$ (1,468,122)	\$ (1,561,565)	\$ (1,667,668)	\$ (1,695,047)	\$ (3,311,540)	\$ (2,087,735)	\$ (1,586,570)	\$ (1,765,138)	\$ (1,909,534)	\$ (2,661,342)	\$ (5,242)	\$ (21,169,032)
Rent Adjustments/Reversals	(256,958)	-	-	-	-	-	-	-	-	(43,069)	(206,130)	-	(506,157)
Other Non-Cash Credits	(191,692)	(370,503)	(145,196)	(301,849)	(311,485)	(302,057)	(516,204)	(471,444)	(598,055)	(471,662)	(836,066)	(154,770)	(4,670,983)
Total Credits	\$ (1,898,180)	\$ (1,838,625)	\$ (1,706,761)	\$ (1,969,517)	\$ (2,006,531)	\$ (3,613,597)	\$ (2,603,939)	\$ (2,058,014)	\$ (2,363,192)	\$ (2,424,265)	\$ (3,703,538)	\$ (160,012)	\$ (26,346,172)

Note: Other non-rent debits includes items paid by PPLP in the ordinary course of business such as insurance, fleet expenses, pensions, travel and entertainment, etc. Other non-cash credits includes intercompany settlements rather than settlements to cash.

Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

The table below provides further details of the rent charges incurred per year. The majority of the activity between Terramar and PPLP is for rent payments that were settled in cash.

SAP Company Code	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Terramar (504) To PPLP (208)													
Net Rent Charges Incurred per Year	\$1,587,939	\$1,838,978	\$1,734,105	\$2,035,838	\$1,966,874	\$2,737,930	\$2,351,373	\$2,198,353	\$2,310,188	\$2,250,159	\$1,184,649	\$0	\$22,196,386
YE Cumulative Balance	\$562,179	\$621,822	\$710,642	\$874,613	\$1,041,022	\$341,723	\$298,964	\$544,559	\$807,406	\$826,722	(\$435,243)	(\$32,472)	

Year	Rent Charges	Debits	Chrgs/Dr	Cash Settlement	Credits	Cash/Cr
2008	\$ 1,844,898	\$ 2,200,268	84%	\$ 1,449,529	\$ 1,898,180	76%
2009	1,838,978	1,898,269	97%	1,468,122	1,838,625	80%
2010	1,734,105	1,795,581	97%	1,561,565	1,706,761	91%
2011	2,035,838	2,133,488	95%	1,667,668	1,969,517	85%
2012	1,966,874	2,172,940	91%	1,695,047	2,006,531	84%
2013	2,737,930	2,914,298	94%	3,311,540	3,613,597	92%
2014	2,351,373	2,561,180	92%	2,087,735	2,603,939	80%
2015	2,198,353	2,303,609	95%	1,586,570	2,058,014	77%
2016	2,310,188	2,626,039	88%	1,765,138	2,363,192	75%
2017	2,293,228	2,443,581	94%	1,909,534	2,424,265	79%
2018	1,390,779	2,441,573	57%	2,661,342	3,703,538	72%
2019	-	562,783	0%	5,242	160,012	3%
Total	\$22,702,543	\$26,053,609	87%	\$21,169,032	\$26,346,172	80%
Adj.	(506,157)	(506,157)		-	(506,157)	
Total	\$22,196,386	\$25,547,452	87%	\$21,169,032	\$25,840,015	82%

The table to the left provides further details of the rent charges incurred per year. As shown, the rent charges represent the majority of debits in the account (approximately 87% of activity between 2008-2009). The remaining debit activity includes items paid for by PPLP for goods and services such as insurance, fleet expenses, pensions, travel and entertainment, etc. Likewise, the majority of the credits in the account correspond to settlements to cash (82% of activity between 2008-2019), with the remaining credit activity including intercompany settlements rather than cash settlements.

The adjustment shown reconciles the effect of 2 duplicative entries for the May 2008 \$128,479 rent charge, an incorrect July 2018 \$206,130.39 rent charge that was reversed in August 2018 as well as an adjustment of \$43,069 for December 2017. The adjustment is made in order to match the SAP-verified total sum of rent charges incurred between 2008-2019. The duplicative entries net to zero through intercompany corrections.¹

¹As explained in the paragraph above regarding adjustments to the intercompany activity, the following lines reconcile the rent charge amounts:

- \$1,844,897.71 - (\$128,479.16 * 2) = \$1,587,939.39 (2008)
- \$2,293,227.85 - \$43,068.52 = \$2,250,159.33 (2017)
- \$1,390,779.09 - \$206,130.39 = \$1,184,648.70 (2018)